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ZUSAMMENFASSUNG 
 
Seit einigen Jahren gibt es eine deutliche Abnahme sowohl in der Mortalität als auch in 
der Morbidität von Malaria in endemischen Gebieten. Dies ist der Einführung den 
Artemisinin-basierten Kombinationstherapien (ACTs) zu verdanken. Dennoch gehört 
Malaria nach wie vor zu einem der größten Gesundheitsprobleme in Afrika, vor allem 
südlich der Sahara. Das klinische Bild der Malaria wird sowohl vom Parasiten als auch 
von genetischen Faktoren des Wirtes stark beeinflusst. Aus diesem Grund setzt sich die 
vorliegende Arbeit mit möglichen Wirts- und Parasitengenen, die die Malariaanfälligkeit 
und das Behandlungsergebnis erheblich beeinflussen, auseinander. Im ersten Kapitel 
meiner Arbeit beschreibe ich eine einfache und schnelle Methode zur Extraktion nuklearer 
DNA aus Parasiten und habe eine Schleifen-vermittelte isothermale Amplifikations (loop 
mediated isothermal amplification (LAMP)) Methode etabliert, um Malariaparasiten zu 
detektieren. Diese Methode ist robust und schnell. Innerhalb von 45 Minuten werden aus 
Nukleinsäuren visuelle Ergebnisse - mit einem sehr niedrigen Detektionslimit von nur 
einem Plasmodium falciparum Parasiten/µL. Im zweiten Kapitel meiner Arbeit habe ich 
den humanen FOXO3A Varianten, der in der Lage ist das Immunsystem zu modulieren, 
genetisch untersucht. Die mögliche Verbindung des untersuchten FOXO3A Genvarianten 
rs12212067 T>G wurde in Personen mit klinischer Malaria ermittelt. Der untersuchte 
FOXO3A Genvariant konnte mit der Schwere der Malaria in Zusammenhang gebracht 
werden. Im dritten Kapitel meiner Arbeit bewertete ich den Zusammenhang zwischen 
Parasiten Genpolymorphismen mit der therapeutischen Wirksamkeit von Artesunate, 
welches Afrikanischen Kindern entweder in einer dreifachen Dosis oder in einer 
fünffachen Dosis verabreicht wurde. Es konnte gezeigt werden, dass eine dreifach Dosis, 
die intramuskulär verabreicht wird, nicht schlechter ist als die konventionelle fünffache 
Dosis. Darüber hinaus zeigten die Analysen, dass der PfMDR1 N86Y Polymorphismus 
mit einer verspäteten Parasitenbeseitigung einhergeht, unabhängig von dem 
Behandlungsschema. Im vierten Kapitel untersuchte ich den Glukose-6-Phosphate 
Dehydrogenase (G6PD) Mangel, eine genetische Funktionsstörung, die zu einem 
partiellen Schutz gegen Malaria beiträgt. Anhand der Ergebnisse kann festgehalten 
werden, dass schwerer G6PD Mangel mit einer geringeren Hämoglobinkonzentration 
einhergeht und keine Verbindung zur Parasitendichte besteht. Zusammenfassend lässt 
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sich sagen, dass diese Arbeit unterschiedliche Wirts- und Parasitenfaktoren beleuchtet, 
die sowohl die klinische Malaria als auch die therapeutische Wirksamkeit des antimalaria 
Medikamentes Artesunate beeinflussen könnten. 
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ABSTRACT 
 
In recent years, there has been a considerable reduction in malaria morbidity and mortality 
in endemic regions, following the implementation of artemisinin-based combination 
therapies (ACTs) as a first line treatment. Nevertheless, malaria yet remains a major 
public health problem in sub-Saharan Africa. The clinical course of malaria is essentially 
influenced by both parasite and host genetic factors. This dissertation aims to investigate 
possible host and parasite genes that may largely influence the malaria susceptibility and 
treatment outcome, respectively. In the first chapter of my thesis, I have described a 
simple and rapid method for extraction of nuclear DNA from parasites and established a 
loop mediated isothermal amplification (LAMP) methodology to detect malarial parasites. 
This methodology is robust with a turnover time of 45 minutes from nucleic acids isolation 
to visual readout of results, with a limit of detection to as low as one Plasmodium 
falciparum parasite/µL. In the second chapter of my thesis, I have investigated the 
human FOXO3A genetic variant which is known to modulate immune responses. The 
possible associations of the studied FOXO3A gene variant rs12212067 T>G were 
determined in a cohort of individuals with clinical malaria phenotypes. The investigated 
FOXO3A gene variant was associated with the severity of malaria. In the third chapter 
of my dissertation, I evaluated the association of parasite gene polymorphisms with 
therapeutic efficacy of parental artesunate administered to African children either as a 
three or a five dose regimen. The investigations led to the findings that three dose intra-
muscular regimen was not inferior to the conventional five dose regimen. In addition, the 
analysis revealed that the PfMDR1 N86Y polymorphism is associated with delayed 
parasite clearance irrespective of treatment regimen. In the fourth chapter, I investigated 
the glucose-6-phosphate dehydrogenase (G6PD) deficiency, a genetic disorder that is 
demonstrated to confer partial protection from malaria. The investigations led to the 
conclusion that severe G6PD deficiency was associated with a lower hemoglobin 
concentrations and there was no association with parasite densities. Taken together, the 
dissertation provides added value on different host and parasite factors that could 
influence clinical malaria and therapeutic efficacy of antimalarial drug artesunate. 
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1. INTRODUCTION 
1.1. Malaria: Generalities, epidemiology and causative agents 
 
Malaria is a major public health concern in endemic areas. The disease is a vector-borne 
infection caused by an intracellular protozoan parasite belonging to the genus of 
Plasmodium and is transmitted to humans through the infective bite of a female Anopheles 
mosquito [1]. Classified as one of the ancient and widespread infectious diseases [2], 
malaria has evolved both biologically and phylogenetically along with the humans [3]. 
 
Although malaria-related mortality rates and case incidence have considerably reduced 
worldwide by 60% and 37%, respectively between 2000 and 2015, the disease remains a 
major threat with an estimated 3.2 billion people in 95 countries still at risk [4]. In 2015, 
World Health Organization (WHO) reported approximately 214 million cases and about 
438,000 deaths occurring in the world with the highest morbidity and mortality rates 
(~90%) observed in Africa, especially among children under the age of five years [4]. 
 
The seasonal activity and the spatial limits of distribution of malaria are strongly influenced 
by meteorological factors, including temperature, rainfall and humidity [5, 6], and as well 
as by the local capacity to control the disease [5]. Malaria transmission occurs at higher 
rates in the tropical and sub-tropical countries (Figure 1). However, following the Global 
Malaria Eradication Program launched by the WHO in the 1950s, 79 countries 
successfully eliminated malaria. This was mostly achieved in the extra-tropics (Eurasia, 
northern America, most of northern Africa, and Australia) where malaria transmission was 
highly seasonal due to temperate climatic conditions and mainly caused by P. vivax [7]. 
Nevertheless, a possible risk of re-introduction of the disease in these countries is 
constant [7]. 
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Figure 1: Malaria incidence in countries or areas at risk of transmission, 2015. 
Source: World Malaria Report 2015, WHO [4]. 
 
For decades, only four Plasmodium species, malariae, ovale, vivax and falciparum, were 
known to cause human malaria. Later a new species, knowlesi reported to infect humans 
was identified in South-East Asia [8-12]. In 2008, WHO recognized it as the fifth human 
Plasmodium species [13-15]. Among these species, P. falciparum is the most virulent and 
associated with the higher morbidity and mortality observed in affected countries [16]. For 
the disease to be transmitted, a vector, which is a female mosquito of the genus 
Anopheles, is required. 
 
So far, 465 Anopheles species are properly identified [17]. Out of these 465 anopheline 
species, 70 are reported to be the vectors of human malaria [18] with 52 characterized as 
dominant vector species with the ability to transmit malaria at a level of major concern to 
public health [19]. Among these vectors, three namely Anopheles gambiae, Anopheles 
arabiensis and Anopheles funestus are reported to be the most efficient malaria vectors 
in the world [20, 21]. Anopheles gambiae being the main vector of P. falciparum [22]. 
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1.2. Life cycle of Plasmodium spp. 
 
The life cycle of all Plasmodium species is very similar following fundamentally the same 
process with many stages. The development of the Plasmodium involves a host change 
from an arthropod vector to a vertebrate host (Figure 2). The infection starts with the bite 
of an infected female Anopheles mosquito and the injection of sporozoites from the 
salivary glands into the host’s bloodstream. In about 30 minutes, the sporozoites invade 
the hepatocytes and undergo asexual replication that results in the production of 
schizonts. The hepatocytes burst after approximately five days later, releasing merozoites 
which then invade the red blood cells (RBCs), initiating another asexual replication phase 
in the erythrocyte [23]. During nine days, the invaded merozoites develop from the 
trophozoite to the schizont containing 16 to 32 new merozoites which are released and 
re-invade new RBCs. The duration of the cycle in the erythrocyte is species dependent 
and varies between 24 hours (P. knowlesi) and 72 hours (P. malariae) [24]. Meanwhile, 
some parasites differentiate into the sexual forms, the male and female gametocytes, 
which are taken up by a female mosquito during her blood meal. Inside the mosquito mid-
gut, the male gametocyte undergoes a nuclear division, producing eight flagellated 
microgametes that will fertilize the female macrogamete. At the end of the zygote 
development, hundreds of sporozoites are formed, and migrate to the mosquito salivary 
awaiting injection into the human host [24]. 
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Figure 2: The life cycle of Plasmodium parasites. Source: Biamonte et al. 2013 [23]. 
Reprinted with permission from Elsevier Limited. 
 
1.3. Malaria pathophysiology 
 
With a complex pathogenesis, malaria infection has a very broad outcome [25]. The 
clinical presentation of the disease ranges from asymptomatic to severe and complicated 
forms through mild and uncomplicated malaria [26, 27]. 
 
Asymptomatic malaria 
 
The definition of asymptomatic malaria remains a major problem due to the lack of 
standard diagnostic criteria. Many definitions involve the detection of asexual or sexual 
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parasites and an absence of any acute clinical symptoms, usually fever, during a specified 
time frame. Without being always explicit, asymptomatic malaria refers to bloodstream 
infections and does not include dormant liver stages [28]. On another hand, some studies 
have rather used parasitemia thresholds to define asymptomatic malaria. Only cases of 
fever with parasite densities above the predetermined cutoff were therefore considered to 
be symptomatic malaria cases [29]. However, the most widely used diagnosis criteria are 
presence of parasites in peripheral thick blood smears, an axillary temperature < 37.5°C, 
and an absence of malaria-related symptoms [30-33]. In the absence of transmission, the 
asymptomatic carriers constitute a major reservoir of the disease [34] and thus remain a 
significant obstacle in malaria elimination [35]. This is due, in addition to the obvious lack 
of clinical symptoms, and the presence of a submicroscopic parasitemia [36].  
 
The adaptation of the malaria infection to an asymptomatic status is mediated by the 
acquisition of a partial immunity which can lead to a reduction in the acute clinical 
symptoms of the disease [28]. The development of this partial immunity is antigen-specific 
and mediated by exposure to genetically distinct parasite clones [37]. Therefore, in 
settings with high malaria transmission, constant exposure to malaria parasites leads to 
semi immunity and thus being symptom free after infection [38].  
 
The contribution of host factors to this disease state is not fully elucidated. The main 
reason is that the majority of studies are rather focused either on the susceptibility or 
resistance to severe malaria [25, 39]. Earlier investigations reported that mutations in 
mannose binding lectin are significantly associated with the control of parasitemia in 
asymptomatic adults [40]. 
 
Uncomplicated malaria 
 
According to WHO, uncomplicated malaria is a symptomatic disease without signs of 
severity or clinical/laboratory evidence of vital organ dysfunction [41]. Although the 
disease has some clinical manifestations, they are non-specific and mimic that of many 
other infections [42]. The symptoms include a vague absence of wellbeing, fever, fatigue, 
headache, muscle aches and abdominal discomfort [43]. These clinical signs are 
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influenced by the degree of the acquired immunity, parasite factors, and the previous 
exposure [44]. 
 
The association of host polymorphisms such as erythrocyte disorders with uncomplicated 
malaria remains less clear [45]. 
 
Severe malaria 
 
The severity of malaria is mostly caused by P. falciparum. P. vivax and P. ovale can also 
produce serious complications leading to death. However, this is rare [46]. The definition 
of P. falciparum severe malaria follows the WHO criteria [27]. Symptoms and mortality 
depend on the age and malaria transmission [47]. Severe anemia and hypoglycemia are 
more common in children, whereas acute pulmonary edema, acute kidney injury, and 
jaundice are prevalent in adults. Coma (cerebral malaria) and acidosis occur in all age 
groups [48]. However the detailed information supporting the age-dependent severity is 
very scarce [49]. Different phenotypes related to severe malaria have been defined. They 
include severe malarial anemia and cerebral malaria [50]. 
 
The influence of the human factors on susceptibility and resistance to severe malaria has 
been extensively studied and several genetic polymorphisms have been identified to play 
a vital role [51-55]. 
1.4. Diagnosis, treatment and prevention 
 
The diagnostic of malaria is still a challenge in many affected countries [56]. It is 
sometimes only based on clinical signs and symptoms although this method cannot 
differentiate malaria from other tropical diseases [57]. As the disease can quickly progress 
to a severe form, an effective diagnosis based on laboratory findings is necessary in order 
to reduce both complications and mortality. Microscopic examination of stained thin and 
thick blood films using Giemsa remains the gold standard. To improve the quality 
management of the disease, especially in remote areas, WHO has recommended the use 
of rapid diagnostic tests (RDTs), which are based on the detection of the malaria parasite 
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antigens, to supplement light microscopy [58]. Serological methods such as the 
immunofluorescence antibody testing (IFA) have been also used and are based on the 
detection of antibodies against asexual blood stage of parasites. Molecular techniques, 
e.g. polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP) are 
highly sensitive and sophisticated tools for malaria diagnosis [57]. 
 
Malaria is a curable disease. Currently available antimalarial drugs include: cinchona 
alkaloids (quinine and quinidine), 4-methanolquinolines and amyl alcohols (mefloquine, 
lumefantrine and halofantrine), 4-aminoquinolines (chloroquine and amodiaquine), 8-
aminoquinolines (primaquine and tafenoquine), antifolates (sulfadoxine, pyrimethamine, 
dapsone and proguanil), naphthoquinones (atovaquone), non-antifolate antibiotics 
(clindamycin, doxycycline, azythromycin and fosmidomycin) and artemisinins 
(artemisinin, dihydroartemisinin, artemether and artesunate) [59].  
 
The prevention and control of malaria rely on a combination of antivectorial measures, 
including the use of insecticide-treated bed nets and indoor residual spray, and the 
chemoprophylaxis. In addition to the chemoprophylaxis allowed to international travelers, 
WHO also recommend a seasonal malaria chemoprevention for children and pregnant 
women as intermittent preventive treatment in infants (IPTi) and intermittent preventive 
treatment in pregnancy (IPTp), respectively [60]. 
 
Amongst the prevention measures, the vaccines are the most important tools. 
Unfortunately, there is currently no licensed malaria vaccine. The main reasons are the 
absence of immune correlate of protection and the high genetic diversity of parasites. [61]. 
So far, RTS,S, a pre-erythrocytic vaccine, is the most advanced candidate [62-65]. 
 
1.5. Antimalarial drug resistance 
 
In 1973, WHO defined antimalarial drug resistance as the parasite strain ability to multiply 
and/or survive despite the administration and absorption of a drug given in doses equal to 
or higher than those usually recommended but within the limits of tolerance of the subject 
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[66]. A decade later, the definition was amended to specify that the drug in question must 
“gain access to the parasite or the infected red blood cell for the duration of the time 
necessary for its normal action” [67]. 
 
Resistance to antimalarial drugs arises from genetic events resulting from spontaneous 
and rare mutations, including gene duplications [68]. The mechanisms are known to vary 
and include alterations of drug transport and permeability, conversion of the drug to a form 
with lower activity, increased expression of the drug target, and alterations of the drug 
target that lowers its binding affinity [69].  
 
The resistance of Plasmodium to antimalarial drugs started with the appearance and 
spread of mutations on the target of chloroquine [70]. As a consequence, sulfadoxine-
pyrimethamine, an alternative to chloroquine at that time, was introduced. Unfortunately, 
resistance to this drug rapidly evolved, occurring at high frequency in malaria settings [71]. 
Following this additional failure, several other antimalarial drugs , including mefloquine, 
amodiaquine and quinine have since been deployed to fight resistant parasites [72]. 
Presently, artemisinin-based combination therapies (ACTs) highly efficacious drugs are 
used to improve the treatment efficacy and reduce the resistant parasite strains. 
Unfortunately, resistance to ACTs characterized as prolonged parasite clearance is 
already reported in South-East Asia [73].  
 
1.5.1. Host genetics 
 
Although antimalarial drug resistance is particularly associated with mutations in the 
parasites, host genetic factors are also known to play a significant role. The contribution 
of host factors, especially those linked with antimalarial drug metabolism remains poorly 
investigated [74]. Variations in the genes that metabolize drugs may possibly influence its 
clearance through differences in parasite exposure (time and plasma concentrations), and 
consequently prime for drug resistance [75]. Therefore, functional studies investigating 
the absorption–distribution–metabolism–excretion (ADME) properties are needed as they 
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may improve our knowledge on the pharmacokinetics and metabolic pathways of these 
drugs.  
1.5.2. Parasite genetics 
 
Drug resistance undeniably hinders the battle against malaria and subsequently increases 
the morbidity and mortality rates. The major cause associated with this phenomenon is 
the mutations found on the parasite protein-target genes. Various parasite proteins, 
including P. falciparum chloroquine resistance transporter (PfCRT) and the multidrug 
resistance-1 (PfMDR1) on the digestive vacuole [76-79], P. falciparum Ca(2+)-ATP6 
(PfATP6) located in the endoplasmic reticulum and suggested to be the artemisinin target 
[80], P. falciparum multidrug resistance protein-1 (PfMDRP1) found on the parasite 
plasma membrane [81], and the Kelch propeller domain (K-13) [82, 83] are associated 
with decrease parasite susceptibility to antimalarial drugs. However, there are no specific 
markers that can be widely used to monitor artemisinin resistance. In that regard, 
polymorphisms in the K-13 gene have been suggested as perfect ones [82]. Unfortunately, 
the mutations in K-13 associated with delayed parasite clearance in South-East Asia are 
absent in Africa [84, 85]. 
 
1.6. Immune response and severe malaria  
 
The host immune system through both the adaptive and innate responses plays an 
essential role during malaria infection. After a repeated exposure to infection, individuals 
in endemic settings acquire some mechanisms which limit the inflammatory response and 
kill or inhibit the parasite replication [86]. This suggests that the outcome of malaria 
infections is probably determined by a delicate balance between pro-inflammatory and 
regulatory responses. The timing, the source and the site of these reactions being critical 
[87]. In response to P. falciparum malaria infection, various elements of the immune 
system such as macrophages and other important cellular effectors, molecules and 
cytokines will activate the immune system [88]. 
 
18 
Among these immune elements, two cytokines, interferon γ (IFN-γ) and tumor necrosis 
factor (TNF) have been extensively studied as there are considered to be important for 
the destruction of the parasites [89]. Concerning the regulatory T cells (Tregs), key 
mediators of immune homeostasis, their role has recently received more focus [90]. 
 
During malaria infection, the induction of soluble immune mediators such interleukin-2 (IL-
2), IL-10 and the transforming growth factor-beta (TGF-ß) via the induction and expansion 
of Tregs by the parasites has been reported to down-regulate the inflammatory responses 
[91]. Such specialized functions of the Tregs are mediated by the transcription factor 
FOXO3 [92], which is also involved in the regulation of several immune functions in 
dendritic and T cells [93] as well as in macrophages [94]. 
 
As a consequence of selection arising after exposure to various pathogens and also the 
need to prevent a self-destruction, the immune system genes are very polymorphic [95]. 
Genetic mutations in loci associated with Treg activity have been suggested to underlie 
both susceptibility to infection and level of Treg expression [96]. Previous studies of Hanel 
et al. [97] on the transcription factor FOXP3 revealed an association of promoter 
polymorphisms with the level of Treg expression and the susceptibility to parasitic 
infection. Recently, a polymorphism in the intronic FOXO3A region was identified and 
linked to the differential outcomes in inflammatory and infectious diseases [98]. 
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2. AIMS 
 
This thesis is a work that was part of the German-African cooperation project. The project 
was a sub-study of a large multicenter clinical trial study comparing the therapeutic 
efficacy of a simplified intravenous (i.v) and intramuscular (i.m) regimens of artesunate to 
the WHO-recommended regimen in African children with severe P. falciparum malaria. 
The major aim was to systematically investigate the contributions of the parasite and host 
genetic factors to clinical malaria and therapeutic efficacy. 
 
To achieve these goals, distinct studies were performed using samples of individuals with 
asymptomatic infection, and severe P. falciparum malaria. The effects of the host genetics 
on the susceptibility to severe malaria, and the contribution of the parasite genetic factors 
to the therapeutic response were investigated. 
 
More specifically, the objectives of the work presented in this dissertation are as follows: 
 
 To standardize and implement a method for rapid isolation of nucleic acids using 
microwave irradiation and identification of Plasmodium spp using LAMP assay 
(Paper I) 
 
 To investigate the contribution of host genetics to the differential disease prognosis 
during P. falciparum malaria (Paper II) 
 
 To evaluate the efficacy of simplified regimens of artesunate, and determine the 
relationship between parasite genetics and therapeutic response (Paper III) 
 
 To investigate the association of host genetics with the clinical parameters during 
severe P. falciparum malaria (Paper IV) 
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3. RESULTS 
 
The results of each paper are summarized into this section. The references are made to 
the tables and figures in the different publications. 
3.1. Paper I 
 
A reliable and rapid method for molecular detection of malarial parasites using 
microwave irradiation and loop mediated isothermal amplification 
 
Julia R Port#, Christian Nguetse#, Selorme Adupko, Thirumalaisamy P. Velavan. 
#Equal contribution. 
 
Malaria Journal 2014, 13(1):454. 
 
An appropriate diagnosis of malaria is important for the substantial reduction of avoidable 
deaths. So far light microscopy remains the gold standard. However, rapid molecular 
diagnostic tests appear as an important alternative. 
 
In this study, the microwave-based irradiation source was transformed into a standardized 
extraction-based technique for nucleic acids isolation from human blood and malaria 
parasite. In addition, a loop-mediated isothermal amplification (LAMP) methodology for 
the detection of the parasites was implemented. Blood samples collected in heparinized 
tubes or by finger prick and stored on sterile Whatman filter paper from Gabonese patients 
with severe P. falciparum malaria were used to validate the novel assay. The sensitivity 
of the conventional PCR and LAMP assays was established based on repeated dilution 
series till negativity of ring stage parasites from 3D7 cultures. 
 
Following microwave irradiation, DNA containing vapor droplets were used for successful 
amplification of the PfMDR1 gene of P. falciparum (Figure 2 - Paper I). The limit of 
detection for conventional PCR was up to five parasites/µL (Figure 3 – Paper I) whereas 
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the LAMP methodology was capable to detect as low as one parasite/µL (Figure 4 - Paper 
I) with a turnover time of 45 minutes. 
 
In this study, a new standardized method for malaria diagnosis is presented. With the lack 
of sophisticated equipment in developing countries, this methodology may improve the 
diagnostic and the therapeutic interventions of malaria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 
3.2. Paper II 
 
FOXO3A regulatory polymorphism and susceptibility to severe malaria in 
Gabonese children 
 
Christian N. Nguetse, Peter G. Kremsner, Thirumalaisamy P. Velavan. 
 
Immunogenetics 2015 Feb; 67(2):67-71. 
 
In individuals affected with malaria, the clinical course of the disease varies. The genetic 
factors of the human host have been reported to influence the prognosis of malaria. 
Following an infection, an array of pro- and anti-inflammatory molecules are released. 
Among the molecules involved in the modulation of these inflammatory responses, the 
role of the transcription factor FOXO3 in mediating distinct functions of the regulatory T 
cell populations has been recently acknowledged. 
 
The possible associations of the FOXO3A variant rs12212067T>G which has been 
associated with the prognosis of distinct inflammatory and infectious diseases were 
investigated in this study. A group of Gabonese children infected with P. falciparum were 
enrolled into the study, and the severe cases of malaria were compared to those with 
asymptomatic/mild cases. 
 
The statistical analyses revealed that the FOXO3A polymorphism rs12212067T>G was 
significantly associated with the severe malaria phenotype following the allelic (OR=1.54, 
95% CI=1.15–2.05, P=0.0028) and dominant (OR=1.94, 95 % CI=1.36–2.77,  
P=0.0002) models (Table 1 – Paper II). 
 
This study unravels the pivotal role of the FOXO3-dependent pathway in malaria as it 
demonstrates the contribution of the FOXO3A variant rs12212067T>G to the increased 
inflammatory responses to P. falciparum malaria. 
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3.3. Paper III 
 
Intramuscular artesunate for severe malaria in African children: a multicentre, 
randomised controlled trial 
 
Peter G. Kremsner, Akim A. Adegnika, Aurore B. Hounkpatin, Jeannot F. Zinsou, Terrie 
E. Taylor, Yamikani Chimalizeni, Alice Liomba, Maryvonne Kombila, Marielle K. Bouyou-
Akotet, Denise P. Mawili Mboumba, Tsiri Agbenyega, Daniel Ansong, Justice Sylverken, 
Bernhards R. Ogutu, Godfrey A. Otieno, Anne Wangwe, Kalifa A. Bojang, Uduak 
Okomo, Frank Sanya-Isijola, Charles R. Newton, Patricia Njuguna, Michael Kazungu, 
Reinhold Kerb, Mirjam Geditz, Matthias Schwab, Thirumalaisamy P. Velavan, Christian 
Nguetse, Carsten Köhler, Saadou Issifou, Stefanie Bolte, Thomas Engleitner, Benjamin 
Mordmüller, Sanjeev Krishna. 
 
PLOS Medicine 2016 Jan 12; 13(1). 
 
The antimalarial drug artesunate is now approved as the front-line treatment for severe 
malaria in both children and adults. A five-dose regimen administered intramuscularly 
(i.m) or intravenously (i.v) is recommended by WHO. However in resources limited-
settings, its practicability is a great challenge as finding and maintaining i.v access, 
especially in children to ensure that correct doses are given on time is difficult. Therefore 
a simpler regimen is really needed and would be preferable. 
 
A simplified (once daily during 3 days) dose regimen i.v artesunate has been previously 
investigated and reported to be non-inferior to the complex 5-dose regimen. However, its 
appraisal has since remained a long debate urging to investigate the i.m route as this has 
received so far or not little attention. 
 
Intramuscular artesunate (total dose 12 mg/kg) split into simplified once daily 3-dose 
regimen (4 mg/kg) was compared for non-inferiority to the WHO-recommended 5-dose 
regimen in African children with severe malaria enrolled into a multicenter clinical trial. In 
addition to the primary and secondary objectives investigating the non-inferiority of the 
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simplified regimens, and comparing the tolerability and safety, respectively, analysis of 
the influence of parasites genetic factors on parasite clearance was done. 
 
The results of the primary efficacy endpoint defined as the proportion of patient with ≥ 
99% parasite reduction from the baseline parasitemia at 24±1 h demonstrate that in both 
the per protocol and intended to treat populations 3-dose i.m of artesunate was non-
inferior to the 5-dose standard i.m regimen (Figures 3 and 4 – Paper III). In addition, the 
time to 99% parasite clearance was comparable between the treatment groups.  
 
The investigation of the influence of the parasite genetics on the parasite clearance (PC) 
estimates revealed that PfMDR1 N86Y was significantly associated with delayed time to 
100% and 99% parasite clearance of 4.8 h (95% CI 1.9 – 7.6 h; P< 0.001) and 2.8 h (95% 
CI 0.9 – 4.8 h; P= 0.005), respectively.  
 
The major drawback associated with parenteral artesunate is the occurrence of delayed 
hemolytic anemia happening between one to two weeks after treatment. Our 
investigations revealed a significant association between delayed anemia with the 
leukocyte count (P<0.001). Patients with delayed anemia had a significantly higher 
leukocytes count at Day 7 (Figure 8 – Paper III).  
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3.4. Paper IV 
 
Glucose-6-phosphate dehydrogenase deficiency and reduced haemoglobin levels 
in African children with severe malaria. 
 
Christian N. Nguetse, Christian G. Meyer, Ayola Akim Adegnika, Tsiri Agbenyega, 
Bernhards R. Ogutu, Peter G. Kremsner, Thirumalaisamy P. Velavan. 
 
Malaria Journal 2016 Jul 7; 15(1):346.  
 
Red blood cell polymorphisms, including glucose-6-phosphate dehydrogenase (G6PD) 
deficiency confer relative protection against severe malaria. G6PD is a key enzyme 
involved in the pentose phosphate pathway and provides a reduced form of nicotinamide 
adenine dinucleotide phosphate which helps the erythrocytes to counterbalance the 
oxidative stress. G6PD deficiency is an X-linked inherited disorder with three most 
common variants [376A (G6PD type B), 376G (G6PD deficiency type A+) and 202A 
(severe G6PD deficiency type A-)] prevalent in the African populations. We undertook this 
study to assess the effect of the 202A allele on the clinical presentation of severe malaria 
among African children. 
 
The analysis revealed an overall prevalence of G6PD deficiency of 13% [36/278; 3% 
(4/132) female homozygous and 22% (32/146) male hemizygous]. The frequency of the 
other phenotypes was 14% (40/278) of female heterozygous and 73% (202/278) of G6PD 
normal [67% (88/132) females and 78% (114/146) males] children (Table 2 – Paper IV). 
The multivariate regression analysis showed that the moderately (type A+) and severely 
(type A-) deficient alleles were significantly associated with lower hemoglobin 
concentrations according to the baseline data [P<0.0001, (G6PD heterozygous: 
P<0.0001), (G6PD deficient: P=0.009)] without leading to SMA (P=0.66). There was no 
association of the G6PD alleles with the baseline parasite densities. 
 
 
 
26 
4. GENERAL DISCUSSION AND CONCLUSION 
 
An important factor for the efficient management of malaria is the accurate and prompt 
diagnosis. The observation of Giemsa-stained blood smears using light microscopy 
remains the gold standard. However the technique is time and labor consuming and 
sometimes inaccurate as it requires considerable training and experience. As an 
alternative, immunochromatography-based rapid diagnostic tests (RDTs) were introduced 
but they showed limitations in detecting lower parasitemia. Molecular techniques such as 
the polymerase chain reaction (PCR) assays are highly sensitivity but require long time to 
get a result, expensive and sophisticated equipment. This makes their use difficult for 
point of care diagnostic tool in poor settings. The development of an alternative method 
that can combine speed and sensitivity will be advantageous. In that regard, a loop-
mediated isothermal amplification (LAMP) method was developed. It amplifies the DNA 
with high specificity, efficiency and rapidity under isothermal conditions [99]. LAMP was 
primarily applied to pathogens causing food-borne disease before assays for a variety of 
viruses, including those responsible for severe acute respiratory syndrome (SARS), 
influenza, measles, human papilloma virus disease, and mumps, diseases of resource-
limited settings such as human immunodeficiency virus (HIV), tuberculosis and African 
trypanosomiasis were developed [100]. The first primer sets for malaria targeted the 18S 
ribosomal RNA gene [101] and subsequently the mitochondrial DNA [102].  
 
Together with high quality DNA, molecular assays are modern tools to improve detection 
of malaria cases [103]. As the extraction method is critical for the downstream 
applications, different methods have been developed to remove the inhibitory effect of 
blood during sample preparation [104-106]. However, they are labor-intensive, time-
consuming, sample specific, subject to potential loss of the targeted microorganism or 
nucleic acid, and finally not suitable for automation [107].  
 
In the first study, in attempts to simplify the procedure for DNA extraction and purification, 
we described a rapid and reliable procedure for nucleic acids isolation from human blood 
and malaria parasites using microwave irradiation. Additionally, we described a LAMP 
methodology for the molecular detection of malarial parasites. 
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The application of the microwave irradiation technique for the extraction of DNA and 
detection of some microorganisms such as HIV virus has been reported some decades 
ago [108-110]. Additional reagents or distilled water were used to facilitate the cytolysis, 
dilute the hemoglobin content and thus reduce its inhibitory effect on PCR [108]. In our 
study, we used phosphate buffered saline (PBS) solution only to elute the blood stored on 
filter paper during microwave irradiation treatment and alternatively for enduring storage. 
Although the use of PBS caused a certain decrease of sensitivity due to the dilution, the 
sensitivity levels were comparable to that of commercial kits. Besides, we were able to 
isolate DNA from fresh and archived blood samples and test by PCR and LAMP assays. 
 
In malaria endemic settings, the prevalence of submicroscopic and asymptomatic 
parasitemia is very common, and these cases are sometimes misdiagnosed by the 
microscopy. To improve the malaria control strategies, there is therefore a need for a 
diagnostic tool able to detect subclinical infections such as the asymptomatic careers who 
contribute in maintaining the disease transmission and the endemicity [111-113]. In that 
regards, LAMP for malaria has been shown to reliably detect low parasitemic infections 
[114]. Another positive point of the LAMP methodology is its rapidity in achieving the 
result. Unlike the microscopy and other molecular diagnostic tools such PCR, LAMP is 
very fast as we demonstrated in our study. In fact, we achieved a final visual readout in 
45 minutes. In developing countries and malaria endemic areas where the evolution of 
the disease to a severe case with a fatal outcome is very fast, we believe that LAMP will 
be a best alternative diagnostic tool. 
 
However, like other molecular techniques, LAMP is also subject to contamination which 
can lead to false positive results. We therefore proposed to use the hydroxynaphthol blue 
(HNB) which is directly added to the primary reaction mixture. Nevertheless, the use of 
HNB may be a potential limitation of the LAMP methodology described here. In fact, this 
dye is sensitive to changes in pH and metal ion concentrations. Therefore, it is important 
to respect the concentrations of calcium, magnesium and pH of the master mix, as well 
as the DNA extraction method which may content reagents that affect the pH and metal 
ion concentrations [115]. 
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Exposure of humans to changing environments associated with the differences in climate 
and pathogens, acted as selective forces, obliging them to adapt in order to survive [116-
118]. Understanding of the type and intensity of the selection acting on human genome 
can help to identify the genes involved in rare, severe diseases or in susceptibility to 
complex diseases [119]. A plethora of studies have identified multiple signatures of 
selection in response to malaria (Review in [120]).  
 
In malaria-affected individuals, the outcome of the disease will significantly vary and little 
is known about the mechanisms leading to this differential prognosis. The host immune 
system is suggested to play an essential role. Accumulated evidences show that malaria 
parasites trigger the secretion of many immune soluble mediators through the induction 
and expansion of regulatory T cells (Tregs) which will in turn down-regulate the 
inflammatory responses [91]. During infection, Tregs play an important role in controlling 
the immune responses and contributing to the stability of the immune homeostasis [121, 
122]. This is mediated by the suppressive mechanisms of Tregs done via cell-cell 
interactions and/or production of suppressor cytokines such as interleukin-10 (IL-10) and 
transforming growth factor-beta (TGF-ß) [123], cytotoxic T lymphocyte-associated antigen 
4 (CTLA-4) [124] and the programmed death (PD-1) [125, 126]. This mediation being 
strongly modulated by the FOXO3 transcription factor [93]. 
 
In the second study, we investigated the impact of the FOXO3A mutation rs12212067T>G 
on the outcome of malaria in the Gabonese population. Interestingly, our results showed 
that the minor allele G of this intronic variant was significantly associated with the 
increased risk of severe malaria. This suggests that FOXO3A interfere with the 
inflammatory responses in humans. Such association of the FOXO3 mutations with a fatal 
disease outcome was previously reported with parthenogenesis and ovarian cancer in 
mice [127]. The underlying mechanisms are suggested to be via monocytes, important 
immune cells involved in the inflammatory responses during infectious diseases [98, 128]. 
In the case of severe malaria, FOXO3 is reported to limit the inflammatory responses in 
monocytes, which through the TGF-ß1, restricts the production of pro-inflammatory 
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cytokines, including tumor necrosis factor alpha (TNFα) and increases the production of 
anti-inflammatory cytokines such as IL-10 [98]. 
 
P. falciparum severe malaria accounts for the higher rates of mortality and morbidity 
observed in endemic settings. Till today there is not licensed vaccine to improve the 
malaria control strategies. Therefore, treatment with efficacious antimalarial drugs 
remains an appropriate solution for the management of the disease [129]. Based on the 
results of two large multicenter randomized controlled trials [130, 131], parenteral 
artesunate has been recommended as frontline treatment for severe malaria. However, 
population pharmacokinetic analyses showed that the drug properties may be or are 
altered by pregnancy, acute malaria infection [132], and body weight [133]. Therefore the 
selection of the route of administration is important. In that regard, studies to optimize the 
dosing regimens are needed, especially as the artesunate regimens for severe malaria 
are complex [129]. 
 
The WHO-recommended 5-dose regimen is practicably challenging in resources-limited 
settings. A simpler regimen has the advantages that it will help the healthcare workers to 
ensure that the correct doses are administrated on time.  
 
In the third study, we investigated the efficacy of simplified 3-dose i.v and i.m regimens in 
African children with severe malaria. A particular focus was on the i.m regimen as there 
are limited pharmacokinetic data on i.m artesunate with respect to this population [133]. 
For comparison to the standard regimen, pharmacodynamic endpoints based on parasite 
clearance, a visible measure of the effectiveness of the drug, were used instead of 
pharmacokinetic variables [134]. The results demonstrated that the simplified i.m regimen, 
associated with a faster parasite clearance kinetics, is as efficacious as the 5-dose i.m 
regimen. Therefore, it is a preferable route for administration of antimalarial drugs in small 
children [135]. 
 
The pharmacokinetics of antimalarials might be influenced by numerous factors including 
the disease and the host parameters such as age, sex and weight [132, 133, 136]. 
However, in our study the analyses showed that the 3 regimens were of comparable 
30 
efficacy. These findings are in agreement with previous studies [133, 137]. They support 
the idea that a simplified once daily artesunate in higher dose (4 mg/kg) is sufficient to 
significantly reduce parasitemia. 
 
We also assessed the effects of P. falciparum mutations on the drug susceptibility. We 
found that the PfMDR1 N86Y mutation was associated with decreased parasite sensitivity 
to artesunate in vivo. Mutations in the PfMDR1 gene have been associated with 
contradictory results ranging from no effect, decreased, or increased sensitivity to 
artemisinins in in vitro assays [138-141]. Our findings suggest a constant monitoring of 
parasites susceptibility to artemisinin compounds. 
 
Although highly efficacious for treating severe malaria, many reports have revealed the 
appearance of delayed hemolysis between one to four weeks after treatment with 
parenteral artesunate [142]. The drug quality was suspected to be the plausible 
explanation [143]. However, a recent case of severe delayed hemolysis linked with GMP-
certified artesunate [144], suggested no relation with the drug quality. 
 
In our study, 22 % of children had delayed anemia defined as Hb ≤ 7g/dL seven days or 
more after admission. The analyses did not show any relationship with pharmacokinetic 
parameters for artesunate, dihydroartemisinin or dihydroartemisinin glucuronide (DHAG), 
sickle cell disease and G6PD deficiency. On the contrary, a higher leucocyte (neutrophil) 
count on Day 7 was significantly associated with delayed anemia. These findings suggest 
that delayed hemolysis might be related to the drug toxicity [145] and drug-dependent 
antibodies through an immune-related mechanism [146] rather than sickle cell disease 
and G6PD deficiency [147]. 
 
The investigations on susceptibility and protection against malaria have recognized the 
contribution of host genetic factors. These factors largely involve the red blood cell 
polymorphisms, including the glucose-6-phosphate dehydrogenase (G6PD) deficiency. 
As a consequence of the strong evolutionary pressure of malaria on the human genome, 
the frequencies of G6PD deficiency have raised [53] and a plethora of previous studies 
have reported a positive correlation between the appearance of G6PD deficiency and 
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malaria endemicity [reviewed in [148]. However, their true impact on clinical parameters 
during severe malaria remains not fully understood. 
 
 In the fourth study, we aimed at determining the frequency distribution of G6PD deficiency 
in malaria African children, and investigating the effects of G6PD genotypes on parasite 
densities, hemoglobin levels and severe malarial anemia during admission. Although 
many mutations in the G6PD gene have been identified and associated with low enzyme 
activity [149, 150], the most relevant three variants [376A (G6PD type B, no deficiency), 
376G (moderate G6PD deficiency type A+) and 202A severe G6PD deficiency type A−] in 
Africa [151] were genotyped to determine the prevalence of G6PD deficiency in this study. 
The other variants being reported at a substantially lower frequencies [152, 153]. Our 
analyses revealed that the prevalence of G6PD deficiency substantially increased in our 
study in comparison to previous reports [39, 154-156]. The presence of G6PD deficiency 
and consequently its rise in prevalence in Africa hinder the world strategy of malaria 
elimination as it prevents the use of primaquine, an antimalarial drug effective for both 
transmission blocking of P. falciparum and anti-relapse treatment against P. vivax. In fact, 
primaquine is known to cause hemolytic anemia in G6PD deficient individuals [157]. 
 
During malaria infection, the elimination of parasitized red blood cells by the spleen 
contributes to the reduction of the number of circulating erythrocytes and consequently 
leads to anemia. We may then expect that in severely G6PD deficient individuals, the 
removal of infected erythrocytes associated with the reduced lifespan of red blood cells 
due to subclinical hemolysis [158] might significantly decrease the hemoglobin 
concentrations and cause severe malarial anemia. Interestingly, our results reveal that 
lower hemoglobin concentrations based on baseline data were significantly associated 
with type A+ and type A− G6PD genotypes. However, this lower hemoglobin levels did not 
lead to severe malarial anemia. Our findings are partially in agreement with the results of 
one of the largest and most comprehensive case-control study conducted in Kenya [159]. 
Like in our study, they found a significant association between G6PD deficiencies with 
lower hemoglobin concentrations at the time of hospital admission. However, in contrast 
to our findings they observed that G6PD deficient children who had lower hemoglobin 
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levels also had an increased risk for severe malarial anemia [159]. The likely explanation 
could be due to the sample size which was rather small in our study. 
 
According to published studies suggesting the impaired ability of parasites to grow and 
replicate, or the rapid clearance of infected erythrocytes [160, 161], we hypothesized that 
the parasite densities might be lower in the G6PD deficient individuals. Unfortunately, our 
analyses did not detect a difference by G6PD status. However, severely G6PD deficient 
children had a lower parasitemia in comparison to others. This finding once again 
suggests that the underlying mechanisms of protection with G6PD deficiency are still to 
be elucidated [159]. 
 
 
CONCLUSION 
 
In the first paper, the standardization and implementation of a reliable and rapid methods 
that improve the extraction of DNA, and the detection of plasmodia is described. These 
new techniques can easily be used in resources-limited settings to help diagnose the low-
density malaria parasitemia. In the second paper, the host factors associated with severe 
P. falciparum malaria phenotype were studied. The findings improve our understanding of 
the genetics of infectious diseases such as malaria. In the third paper, simplified once 
daily 3-dose regimens were investigated for non-inferiority. Interestingly, they showed 
comparable efficacy in the reduction of parasitemia as the standard 5-dose regimen. The 
3-dose i.m appeared to be a recommendable route for parenteral artesunate in febrile 
children. However, the parasite clearance kinetics were impaired by the PfMDR1 N86Y 
mutation. In the last paper of this dissertation, G6PD deficiency was significantly 
associated with lower hemoglobin concentrations during severe malaria at the time of 
hospital admission. However, this was not related to the severe malarial anemia 
experienced by some individuals. In addition, there was no association of G6PD deficiency 
with parasitemia. Taken together, these studies expand our knowledge on the contribution 
of host and parasite genetic factors to malaria susceptibility and progression, and on 
another hand their associations with the treatment response.  
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METHODOLOGY Open Access
A reliable and rapid method for molecular
detection of malarial parasites using microwave
irradiation and loop mediated isothermal
amplification
Julia R Port1†, Christian Nguetse1†, Selorme Adukpo1 and Thirumalaisamy P Velavan1,2*
Abstract
Background: Improved living conditions together with appropriate diagnosis can reduce avoidable malarial deaths
substantially. Microscopy remains the gold standard in the diagnosis of malaria. However, rapid molecular
diagnostic tests (RmDT) are becoming increasingly important and will, most likely, be the diagnostic techniques of
choice in the next years.
Methods: In this study, a rapid and reliable nucleic acid extraction procedure from human blood and malarial
parasites using microwave irradiation as a promising platform is described. In addition, a tailored loop mediated
isothermal amplification (LAMP) methodology that utilizes hydroxynaphthol blue (HNB) and Bst 2.0 DNA
polymerases in molecular detection of malarial parasites is described.
Results: Following microwave irradiation for DNA isolation, conventional PCR assays were able to detect up to five
malaria parasites/μl. The LAMP methodology described here was capable to detect as low as one Plasmodium
falciparum parasite/μl after DNA extraction by microwave irradiation. A turnover time of 45 minutes from nucleic
acid extraction to final visual read-out was achieved.
Conclusions: The described procedure offers a cheap, simple and fast method of molecular detection of malaria
parasites. This test can easily be performed in basic laboratories. The methodology has been validated as a proof of
concept and has specifically be developed for use at low-resource settings. Such RmDTs may aid health providers
to make timely therapeutic interventions in malaria endemic regions.
Keywords: Malaria, Microwave irradiation, Plasmodium, Isothermal amplification, LAMP, Diagnostics, Point-of-care
Background
Malaria remains a major public health problem in sub-
Saharan Africa. Approximately 3.4 billion people are at
risk of malaria worldwide with an incidence of 207 million
cases in 2012 and 627,000 reported deaths [1]. Microscopy
of blood smears is still considered the gold standard
for diagnosing malaria infections. Microscopy, however,
is frequently unable to detect low-density infections and
it requires skilled expertise [2-4]. Consequently, rapid
diagnostic tests (RDT), using blood obtained from finger
pricks, are now widely used, especially where quick and
easy diagnosis of malaria is needed [2,3,5-9]. A major disad-
vantage of RDTs is that they are relatively expensive and
unable to quantify the degree of parasitaemia. In some
cases, lack of sufficient sensitivity of RDTs causes, as does
microscopy, failure to detect low-density infections [10,11].
Highest detection rates and specificity can currently be
achieved only with polymerase chain reaction (PCR) or
real-time PCR (qPCR) assays. These techniques use expen-
sive equipment and reagents as well as functional molecular
biology laboratories and appropriate training of laboratory
staff. For field applications these conditions are often not
fulfilled. In addition, PCR reactions require a rather long
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time from DNA extraction to visual read-out by electro-
phoresis or other confirmatory techniques (~5 hours, if per-
formed in a well equipped laboratory) and are as such not
appropriate when rapid diagnoses are needed.
In the last 10 years, isothermal amplifications, espe-
cially loop-mediated isothermal amplification (LAMP)
[12] has revolutionized the field of molecular diagnostics
by offering rapid and reliable approaches at highest sen-
sitivity levels. In 2006, a study described a first set of
LAMP primers for malaria [13] and LAMP specific
primers for four Plasmodium species infecting humans
were reported in 2007 [14], all targeting the 18 s rRNA
region of the Plasmodium species. Primers were also de-
signed for the genus Plasmodium and for Plasmodium
falciparum, targeting mitochondrial DNA [15]. A com-
mercial kit for malaria LAMP is currently available from
Eiken Chemical Co., Ltd., also targeting this genetic re-
gion of plasmodia. This LAMP assay has successfully
been tested under field conditions for both the18s rRNA
[16] and the mtDNA primers [17,18] and been successful
in clinical evaluation of symptomatic and asymptomatic
infections [10]. Under field conditions, the easy endpoint
visualization of results such as colourimetric change is
most advantageous and, thus, desirable. Due to the nature
of LAMP reactions, the method offers unique opportun-
ities. LAMP amplification causes production of magne-
sium pyro-phosphate precipitates, which may be recorded
as a rise in turbidity. Such observations are difficult to
make for untrained staff and an extra step of visualization
would be advantageous. Similar to gel electrophoresis,
where LAMP results are visualized by intercalating sub-
stances such as SYBR Green© or ethidium-bromide,
hydroxynaphtholblue (HNB) can be applied as a potent
detection system. As discussed previously [19], SYBR
Green© and HNB, usually applied in metal ion titration
[20], show higher sensitivity than calcein, which may also
be used in LAMP reactions. HNB has been described to
be superior to SYBR Green©, as no further equipment is
needed for the final read-out and the risk of contamin-
ation is minimized as the dye solution is added directly to
the reaction mix before amplification [19]. Calcein, a
chemical dye quenched with manganese ions may also
serve as a fluorescent dye in LAMP reactions. During
amplification, the manganese ions are released by pyro-
phosphate ions generated, resulting in fluorescence. In
addition, the free calcein combines with magnesium ions
in the LAMP reaction mixture to enhance fluorescent
emissions. Compared to SYBR Green© and calcein, HNB
is the cheapest dye and successful use of HNB LAMP has
recently been demonstrated to be effective in detecting
amplified DNA from malaria parasites [21].
The first critical step in standard molecular diagnostics
of infectious agents is extraction of DNA. Due to interfer-
ence with haem, direct DNA amplification from whole
blood is difficult to achieve. Therefore, the DNA extrac-
tion and purification steps are crucial for subsequent
applications. As LAMP is more robust than are standard
PCR assays, the extraction step is not that important.
Cheap and easy methods have been described using heat
denaturation or chemical lysis. In combination with the
Eiken LAMP kit, a “boil and spin” method and the “PURE”
method, i.e. a simple DNA isolation technique by water
bath or thermoblock, are advised for DNA isolation under
field applications. An alternative is offered by employing
microwave irradiation, which was first described in 1991
[22] and 1995 for hepatitis B virus (HBV) DNA from
serum [23], and for extraction of Toxoplasma gondii de-
rived DNA in 2010 [24]. Downstream applications may
directly be performed without prior purification measures.
Here, a microwave extraction method was established,
along with a tailored LAMP approach for diagnosing
malaria. The microwave extraction method was tested
for parasite and human genes derived from clinical sam-
ples. Sensitivity was tested in repeated serial dilutions
and the quality was compared to reference extraction
methods using a commercial kit.
Methods
Study samples
Whole venous blood samples were collected either into
heparinized tubes (5 mls) or by finger prick (5–10 μl) with
blood stored on sterile Whatman filter paper at admission
to the Albert Schweitzer Hospital, Lambaréné, Gabon,
from patients suffering from severe P. falciparum infec-
tions [25]. Heparinized samples were kept at −80°C until
shipment to Germany at −20°C, while blood spots were
air-dried and stored in clean, sealed plastic bags at room
temperature. Equal volumes of blood were also collected
from healthy adult volunteers in Lambaréné.
Parasite cultures and repeated dilution series
Plasmodium falciparum parasite strain 3D7 were kept in
culture, synchronized with D-sorbitol in their ring stages.
Culture-adapted parasites were then used for extraction
procedures and LAMP assays, applying serial dilutions. In
brief, following the determination of the parasitaemia by
microscopy, the culture was centrifuged to obtain packed
cells which contained 107 cells/μl. Fresh whole blood was
subsequently used to spike the culture and dilution series
were repeatedly made, ranging from calculated 500,000
parasites/μl to 1 parasite/μl and eventual negativity. Equal
volumes of these dilution series were further used for gen-
omic DNA extraction by microwave irradiation and, sub-
sequently, for standard PCR and tailored LAMP assays.
DNA extraction: microwave irradiation
First, DNA was extracted from whole blood samples as
well as from the cultured parasites of the dilution series
Port et al. Malaria Journal 2014, 13:454 Page 2 of 8
http://www.malariajournal.com/content/13/1/454
using the conventional QIAamp DNA mini blood kit
based extraction procedure (Qiagen, Hilden, Germany)
following the manufacturer’s instructions. Next, three
standard operation procedures (SOPs) were established
for microwave irradiation based DNA extraction (MDA
oven, model number: MW17M70G-AU, 230 V, 50 HZ).
The three SOPs were designed to apply in processing (i)
fresh whole blood, (ii) archived blood samples in hepa-
rinized tubes and for (iii) small amounts of blood stored
at ambient temperature and eluted from filter paper in
30 μl PBS. Volumes of 10 μl of blood were transferred
into 0.5 ml tubes and treated at 800 W for 2 minutes
until precipitated and condensed droplets were visible
on and retrievable from the tube walls. One μl of the
clear precipitated watery solution containing DNA was
taken from the walls or the lid of the tube for further
use (Figure 1). Alternatively, for enduring storage, 30 μl
of sterile phosphate buffer saline (PBS) were added to
the irradiated sample. Notably, smaller tubes than those
of 0.5 ml volumes should not be used in the irradiation
procedure as they might break and be destroyed due to
air expansion and, thus, might bear the danger of con-
tamination hazards.
Amplification using standard PCR
As an example, a nested PCR assay targeting the pfmdr1
gene of P. falciparum was applied as described elsewhere
[4]. For each PCR reaction, positive and negative con-
trols were included. Reaction volumes consisted of 20 μl
containing 1× Coral load PCR buffer, 0.25 mM of each
deoxynucleotide-triphosphate (dNTP), 1 U Taq Poly-
merase (Qiagen) and 0.2 μM of each primer. The tem-
plate was 1 μl of the condensed watery solution after
DNA extraction by microwave irradiation. Amplification
was performed as follows: 35 cycles with an initial de-
naturation step at 94°C for 5 min, denaturation at 94°C
for 30 sec, annealing at 55°C (outer primers) or 60°C
(nested primers) for 30 sec, extension at 65°C for 1 min
and final extension at 65°C for 5 min. Amplicons were
subjected to electrophoresis on a 1.2% agarose gel
stained with SYBR green I in 1× Tris-buffered electro-
phoresis buffer (90 mM Tris-acetate, pH 8.0, 90 mM
boric acid, 2.5 mM EDTA). In addition and for confirm-
ation of the specificity of the amplification process, 1 μl
of the purified product was directly used as template for
direct sequencing, using the BigDye terminator v.1.1 cycle
sequencing kit (Applied Biosystems, Foster City, CA,
USA) on an ABI 3130XL DNA sequencer. Results were
confirmed visually from the sequencing electrophero-
grams. Notably, both the DNA extraction procedure has
also be performed to extract human DNA for standard
PCR reactions.
Tailored LAMP assays
Primer design and reagents
LAMP primer pairs for P. falciparum, as published [14],
were provided by Eurofins MWG Synthesis GmbH,
Ebersberg, Germany (Table 1). Bst 2.0 WarmStart™ DNA
Figure 1 Microwave irradiated finger prick blood sample 10 μl fresh finger prick blood collected by capillary (A) before and (B) after
microwave irradiation. Formation of vapour and condensed droplets can be observed on the walls and in the lid.
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Polymerase (New England BioLabs GmbH, Frankfurt am
Main, Germany) was used. This cheap polymerase was
specifically designed for high throughput assays and field
applications. The polymerase may be stored under up
to 45°C without requiring refrigeration. HNB (Fluka,
Sigma-Aldrich, St. Luis, USA) was used as the visualization
dye. In addition, a 3 mM stock solution of HNB was pre-
pared and stored at room temperature [21,26]. Isothermal
reaction buffer was prepared as a 2× working solution.
After thawing, 2.8 mM of dNTPs were added. Betaine solu-
tion for enhancing the polymerase activity and reducing the
formation of secondary structures in GC-rich regions was
purchased from Sigma Aldrich, Munich, Germany.
LAMP Assays
Reactions were performed at 60°C in volumes of 25 μl
containing 1.6 μM FIP, 1 μM BIP, 0.2 μM F3, 0.2 μM B3c,
0,2 μM LPB, 0.4 μM LPF, 120 μM HNB, 2× isothermal re-
action buffer, 1.4 mM dNTPs, 0.4 mM Betaine solution,
8U Bst polymerase and 1 μL of watery DNA solution as
template, following the STARD guidelines for diagnostics.
Two heat blocks (Block Thermostat BT200, Kleinfeld
Labortechnik, Gehrden, Germany) were used and pre-
heated to 60°C for DNA amplification for to 45 minutes,
and enzyme inactivation for 2 minutes at 80°C.
Visual detection of amplification/endpoint analysis
The amplicon was visualized through a distinct colour
change and subsequently confirmed by gel electrophoresis.
A change from violet to light sky blue was considered a
positive result of amplification. If the reaction remained
violet, the sample was assessed as being negative. This as-
sessment was performed at daylight. A positive amplifica-
tion was determined by a colour change occurring after a
minimum of 35 minutes. Absence of colour changes was
assigned after 45 minutes. Accordingly, 45 minutes were
set as the time needed to achieve a firm result.
Results
DNA extraction by microwave irradiation, standard PCR
and LAMP assays
Either condensed vapour droplets or blood remains after
microwave irradiation diluted in a 30 μl volume of PBS
proved to be appropriate templates for further processing
in both standard PCR and LAMP assays. DNA extraction
was achieved from various sources, including fresh venous
blood, heparinized and archived samples and blood eluted
from Whatman filter paper. A 0.5 ml tube containing
10 μl of blood inside a microwave oven led to boiling and
partial desiccation of the sample and to the formation of
vapour, which condenses and may be retrieved from the
walls and lids of the tubes (Figure 1). This haem-free con-
densed vapour contains the nucleic acid.
A nested PCR targeting the pfmdr1 gene of P. falciparum
was applied and successful amplification of DNA extracted
from fresh and archived samples as well as from filter pa-
pers by microwave irradiation was achieved (Figure 2). This
applied to both, DNA containing vapour droplets and
blood remains diluted in PBS. For confirmation of specifi-
city of the amplicon, all PCR products were sequenced
and aligned with reference sequences. Correct sequences
of amplification targets were confirmed in all cases. The
amplicons could successfully be applied to SNP analyses of
drug resistance markers. The total time of the entire diag-
nostic procedure was reduced to less than one hour after
sample collection. While maintaining high sensitivity
levels, expensive equipment or reagents are not required.
Analytical sensitivity
The sensitivity of the PCR assays after microwave-based
extraction was established based on repeated dilution
series. Heparin blood was spiked with ring stage parasites
from 3D7 cultures and serially diluted from 500,000 to
one parasite/μl and negativity. DNA was extracted from
all samples applying both standard reference methods and
microwave irradiation. When using standard DNA isola-
tion methods, one parasite/μl could be reliably detected
(Figure 3A). After microwave extraction, five parasites/μl
were detected (Figure 3B).
Loop mediated isothermal amplification
No differences in the amplification sensitivity was ob-
served when comparing results obtained by a standard
Table 1 LAMP Primers targeting Plasmodium 18 s
ribosomal RNA
Plasmodium spp. Primers Sequence 5′ - 3′
Core primers FIP TCGAACTCTAATTCCCCGTTACCTAT
CAGCTTTTGATGTTAGGGT
BIP CGGAGAGGGAGCCTGAGAAATAGA
ATTGGGTAATTTACGCG
F3 GTATCAATCGAGTTTCTGACC
B3c CTTGTCACTACCTCTCTTCT
Loop primers LPF CGTCATAGCCATGTTAGGCC
LPB AGCTACCACATCTAAGGAAGGCAG
P. falciparum Primers Sequence 5′ - 3′
Core primers FIP AGCTGGAATTACCGCGGCTG GGTT
CCTAGAGAAACAATTGG
BIP TGTTGCAGTTAAAACGTTCGTAGCC
CAAACCAGTTTAAATGAAAC
F3 TGTAATTGGAATGATAGGAATTTA
B3c GAAAACCTTATTTTGAACAAAGC
Loop primers LPF GCACCAGACTTGCCCT
LPB TTGAATATTAAAGAA
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thermocycler or a heating block as proposed here. 3D7
parasites, starting at a dilution of 100,000 parasites/μl to
one parasite/μl were subjected to tailored LAMP assays
using the DNA extracted by microwave irradiation. The
parasite content of the diluted culture was assessed by
microscopy, counting 100 oil immersion fields. When
direct condensed vapour droplets were used in LAMP,
positive amplification was observed with a limit of detec-
tion of one parasite/μl (Figure 4A). When blood remains
were diluted in PBS, positive amplification was observed
at a limit of detection of five parasites/μl (Figure 4B).
With HNB used as appropriate dye, negative controls
remained violet, while successful LAMP was character-
ized by a colour change to sky blue. Gel electrophoresis
was applied to verify HNB positive results (Figure 5). Re-
peated tests allowed to set the endpoint of a final deci-
sion on test positivity or negativity at a maximum of
45 minutes.
Discussion
Multiple techniques to extract and purify DNA have
been described and applied to date. Problems arising
from interference with haem, as occurring in extraction
of DNA from venous blood, can easily be circumvented
in laboratories when using commercially available ex-
traction kits, while, in low resource settings, commercial
DNA extraction kits are not always available. Alterna-
tively, intensive heat treatment or shock freezing can
also lyse cells for DNA release. Microwave irradiation
has been shown in this study to successfully extract
DNA from whole blood samples in less than 3 minutes.
No further chemicals are required for isolation or purifi-
cation. DNA isolated by irradiation could be subjected
to both standard PCR amplification and to the LAMP
procedure. The use of PBS, although causing a certain
decrease of sensitivity due to the dilution, was beneficial,
as larger volumes of DNA could be stored. Sensitivity
levels observed after microwave irradiation were close to
those obtained after extraction with commercial kits.
Thus, microwave irradiation offers a cheap, fast and
easy technique that can be applied readily for isothermal
amplification and that may be applied in field settings.
The nucleic acid extraction by microwave irradiation al-
lows to isolate human DNA and nucleic acid materials
from pathogens in blood. Our study demonstrates that
DNA may be extracted from fresh blood samples and
from archived blood samples, either heparinized or
stored on filter papers even after more than a decade.
LAMP for malaria has been shown to detect low parasite
concentrations [17] and to be successfully applicable in
asymptomatic Plasmodium infections. When aiming at
improving malaria control, simple and easy to perform
Figure 2 Amplified pfmdr1 gene products after nested PCR. Standard DNA extraction was carried out using the QIAamp DNA mini
blood kit (Qiagen, Hilden, Germany). DNA extraction by microwave irradiation was performed using a microwave oven (MDA, model number:
MW17M70G-AU, 230 V, 50 HZ, operated at 800 W). 1 μl of condensed droplets after microwave treatment were utilized for the PCR procedures.
First lane: DNA ladder; NC: Negative Control; PC1 and PC2: Standard extraction from archived blood sample and pfmdr1 amplicons at expected
sizes; PC3 and PC4: Standard extraction from 3D7 P. falciparum parasites in culture and pfmdr1 amplicons at expected sizes; ME1 and ME2:
Microwave based extraction from archived blood sample and pfmdr1 amplicons at expected sizes; ME3 and ME4: Microwave based extraction
in 3D7 culture parasites and pfmdr1 amplicons at expected sizes; ME5: Microwave based DNA extraction from fresh blood sample and pfmdr1
amplicons at expected sizes.
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Figure 3 Limit of detection from standard extraction and microwave irradiation procedure. Repeated dilution series were made from
100,000 parasites/μl to one parasite/μl until negativity. Equal volumes of diluted culture were further used for DNA extraction and for standard
PCR assays. A, Serial dilutions including dilutions from 100,000 parasites to negativitiy. The limit of detection was determined to be 1 parasite/μl
culture applying the standard extraction procedure (QIAamp DNA mini blood kit); B, After microwave based DNA extraction the limit of detection
was 5 parasites/μl.
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Figure 4 Limit of detection of parasites extracted by microwave irradiation in tailored LAMP assays. Successful amplification was
characterized by clear colour changes from violet to sky blue and the negative controls remained violet. NC: Negative control; A, Pure condensed
vapour droplets were used as DNA templates. LAMP can detect 1 parasite/μl culture fluid. B, Vapour droplets diluted in PBS. LAMP detects 5
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Figure 5 Visual assessment after 35 minutes following the LAMP assays. All amplicons were confirmed by gel electrophoresis. PC, positive
control after standard DNA extraction; ME, clinical sample, LAMP assay after microwave DNA extraction; HDC, human DNA control; NC,
negative control.
Port et al. Malaria Journal 2014, 13:454 Page 6 of 8
http://www.malariajournal.com/content/13/1/454
diagnostic measures detecting subclinical infections need
to be applied, as asymptomatic carriers play an crucial
role in the transmission cycle of plasmodia and in main-
taining endemicity [27-29]. Further and ongoing studies
will show, whether the microwave extraction/LAMP sys-
tem is also appropriate for the detection of low parasit-
aemia and asymptomatic infections.
An apparent advantage of the system we propose here
is the avoidance of contamination through aerosolic
PCR-generated DNA fragments, as, due to the HNB dye
added to the primary reaction mixture tubes do not need
to be opened for further result confirmation. Another
value of the technique is that the procedure is easy to
perform, does not need technicians trained in molecular
techniques and that the final result is obtained by means
of visual assessment. This has been performed success-
fully by untrained personnel after providing them one
positive and on negative sample result.
In addition to the obvious advantages, the study has
limitations. The minimum size of tubes to be used in
microwave exposure should not be below a capacity of
0.5 ml, as through damage of the tube, contamination
with biological materials might occur. The problem of
potential unavailability of electricity used for irradiation
and heating of thermoblocks in the field needs to be ad-
dressed by identifying alternative power sources for
irradiation and heating. Currently, a prototype that uti-
lizes direct current has been designed for LAMP assays.
First trials applying this hand-held battery operated ther-
moblock for LAMP assays are currently carried out and
evaluated.
Taken together, the method described offers a cheap,
simple and fast technique of molecular detection of mal-
aria parasites. The method has been validated as a proof
of concept to be performed in laboratories with limited
resources.
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Abstract The clinical course of malaria varies between af-
fected individuals and host genetic factors have been shown to
influence the outcome of malaria. The role of FOXO3-driven
pathway in modulating inflammatory responses, including
mediation of distinct functions of regulatory T effector cell
populations (Tregs) by the transcription factor FOXO3, has
recently been recognized. We aimed to study possible associ-
ations of a non-coding polymorphism in intron 2 of the
FOXO3A gene (rs12212067T>G) that was shown earlier to
modulate the FOXO3 expression and to be associated with the
prognosis of distinct inflammatory and infectious diseases.
The FOXO3A polymorphism rs12212067T>G was geno-
typed by direct sequencing in a group of Gabonese children
with confirmed Plasmodium falciparummalaria. Severe cases
of malaria were compared with asymptomatic/mild cases. The
FOXO3A variant rs12212067T>G was associated with the
phenotype of severe malaria, but not with asymptomatic/
mild malaria (allelic model: OR=1.54, 95 % CI=1.15–2.05,
P=0.0028; dominant model: OR=1.94, 95 % CI=1.36–2.77,
P=0.0002). The FOXO3A variant rs12212067T>G is associ-
ated with increased inflammatory responses to Plasmodium
falciparum malaria, indicating a role of the FOXO3-
dependent pathway in malaria.
Keywords FOXO3A . Severemalaria . Tregs . Plasmodium
falciparum . Gabon
Introduction
Malaria is a major public health problem in tropical and sub-
tropical countries and approximately 3.4 billion people are at
risk. In 2012, approximately 207 million cases were docu-
mented and about 627,000 deaths occurred globally (WHO
2013). Highest malaria incidences and mortality rates are
reported from sub-Saharan African (SSA) countries with a
mortality of 77 % among children under the age of 5 years,
depending on the severity of the disease and access to ade-
quate treatment (WHO 2013). Among the five Plasmodium
species causing humanmalaria,Plasmodium falciparum is the
most virulent agent (WHO 2013). Plasmodium falciparum-
infected individuals present with different clinical phenotypes,
ranging from asymptomatic infections to severe and compli-
cated forms of malaria (Miller et al. 2002). Parasites exert a
selective pressure on their hosts and strongly account for
shaping genetic diversity in human populations (Maizels
2009). Previous investigations have shown that human gene
polymorphisms contribute to the variability of malaria pheno-
types (Weatherall and Clegg 2002).
Malaria parasites induce regulatory Tcells (Tregs) which in
turn suppress anti-parasite effector cells. Tregs are a subset of
T cells that function to control immune responses. The prima-
ry role of Tregs is active suppression of several pathological
and physiological host immune responses, thereby contribut-
ing to the maintenance of immune homeostasis. Tregs can
reduce injurious host inflammatory and immune responses
through mechanisms exerted by cell-to-cell contact, inhibitory
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cytokines and by cytokine deprivation (Velavan and
Ojurongbe 2011). Several studies have reported on an associ-
ation between the increased number of Tregs including
CD4+CD25+Foxp3+ T cells and malaria infection (Brustoski
et al. 2006; Scholzen et al. 2009; Vigario et al. 2007). Other
studies have demonstrated the association of functional Treg
cell polymorphisms with malaria (Hanel et al. 2011; Huang
et al. 2012; Koukouikila-Koussounda et al. 2013; Velavan
et al. 2011, 2012). Only little information, however, is avail-
able regarding the induction of Tregs by the parasite. Malaria
parasites trigger the secretion of many pro-inflammatory cy-
tokines, including tumor necrosis factor alpha (TNF-α) by
macrophages and monocytes (Malaguarnera and Musumeci
2002). An earlier study has shown that malaria parasites
induce soluble immune mediators such as IL-2, a T cell
growth factor, the regulatory proteins IL-10, and transforming
growth factor-beta (TGF-ß) through induction and expansion
of Tregs, thereby down-regulating inflammatory responses
(Scholzen et al. 2009). Specialized functions of effector cell
populations of the Tregs are mediated by the transcription
factor FOXO3 (Kerdiles et al. 2010).
Forkhead box O (FOXO) is a subfamily of transcription
factors of the FOX family, which is characterized by a con-
served and distinct forkhead domain, a DNA-binding domain
of about 100 amino acids (Weigel and Jackle 1990). Based on
the sequence similarities in the forkhead box family, more
than 100 members of transcription factors ranging from
FOXA to FOXR, including subgroups, have been classified
in humans (Carter and Brunet 2007). Four of them, FOXO1,
FOXO3, FOXO4, and FOXO6, each encoded by distinct
genes, have been identified in the FOXO family
(Eijkelenboom et al. 2013). FOXO is known to play a role
in modulating the immune response during inflammation,
oxidative stress, and in response to growth factors (Hedrick
et al. 2012). In addition, this subgroup of the forkhead family
is believed to regulate the development and differentiation of
antigen-responsive lymphocyte populations (Hedrick et al.
2012). A considerable number of transcription factors, includ-
ing FOXO3 itself, affects the transcriptional activity of the
FOXO members in exerting a control mechanism between
FOXO and FOXO3 (Essaghir et al. 2009). Regulation of
FOXO components is mediated by recruitment and phosphor-
ylation of the protein kinases B of the AKT family and the
serine/threonine-protein kinase SGK1. This is achieved
through the 3-phosphoinositide-dependent kinase 1 (PDK1)
following activation of phosphoinositide 3-kinase (PI3K) in
response to the growth factor insulin (Alessi et al. 1997;
Stokoe et al. 1997). FOXO3 is expressed in many tissues
and regulates various cellular activities, including DNA repair
mechanisms (Hedrick 2009). In addition, FOXO3 is involved
in the regulation of several immune functions in dendritic and
T cells (Dejean et al. 2009) as well as in macrophages (Litvak
et al. 2012).
Based on previous findings in inflammatory and infectious
diseases and the established role of the intronic FOXO3A
polymorphism rs12212067 (Lee et al. 2013), we studied its
possible association with the phenotype of severe malaria in a
Gabonese study population.
Materials and methods
Study subjects
Patients were recruited at the Albert Schweitzer Hospital,
Lambaréné, Gabon, and the Centre Hospitalier de Libreville,
Gabon. The Gabonese individuals belong to different ethnic
groups but the majority of the individuals in the current study
represent Bantu population. A total of 552 Gabonese children
aged 8 to 140 months with confirmed Plasmodium falciparum
malaria were enrolled. The study group was divided into the
two subgroups of mild malaria (n=255) and severe malaria
(n=297) as performed in previous studies (Kalmbach et al.
2006; Kun et al. 1998). Mild malaria patients were defined as
individuals carrying parasites for days or weeks without de-
veloping any clinically relevant symptoms. The subgroup of
mild malaria was used as the control group. Cases with severe
malaria were children with Plasmodium falciparum
parasitemia classified based on WHO guidelines (WHO
2010). Blood samples from all participants were collected in
heparinized tubes. Storage of specimens was done at −80 °C
for subsequent molecular analyses. Written informed consent
was obtained from parents/guardians of all participating chil-
dren. The study was approved by the local Ethics Committee
of the International Foundation of the Albert Schweitzer
Hospital, Lambaréné, Gabon.
FOXO3A rs12212067 genotyping
Genomic DNA was isolated using the QIAamp DNA mini
blood kit (Qiagen, Hilden, Germany) in order to determine the
frequency distribution of the SNP rs12212067. The fragment
of the FOXO3A gene containing the intronic SNP
rs12212067T>Gwas amplified by PCR using the primer pairs
5′-CGCATACGTTGTTGGAGGTT-3′ (forward) and 5′-
CCCGAGGCTAAATGGAAATGTG-3′ (reverse). Briefly,
10 ng of genomic DNA were added to a 20 μL reaction
mixture containing 1× PCR buffer (20 mM Tris-HCl pH 8.4,
50 mM KCl, 1.5 mM of MgCl2), 0.125 mM of dNTPs,
0.25 mM of each primer, and 1 U Taq DNA polymerase
(Qiagen, Hilden, Germany). The PCR reaction was run on a
PTC-200 Thermal cycler (MJ Research, USA). The thermal
conditions after the initial denaturation (94 °C, 5 min) were
35 cycles of 94 °C for 45 s, 67 °C for 45 s and 72 °C for 1 min.
The PCR was completed with a final extension step of 72 °C
for 5 min. PCR products were visualized through
68 Immunogenetics (2015) 67:67–71
electrophoresis on a 1.2 % agarose gel stained with SYBR
green I in 1× Tris-electrophoresis buffer (90 mM Tris-acetate,
pH 8.0, 90 mM boric acid, 2.5 mM EDTA).
Subsequently, PCR products were purified (Exo-SAP-IT,
USB, Affymetrix, USA) and directly used as templates for
DNA sequencing using the BigDye terminator v. 1.1 cycle
sequencing kit (Applied Biosystems, USA) on an ABI
3130XL DNA sequencer. The polymorphism was identified
by assembling the sequences with the reference sequence of
FOXO3A gene (NT_025741.15) using the CodonCode
Aligner 4.0 software (http://www.codoncode.com/) and
visually reconfirmed from their electropherograms.
Statistical analysis
The data were analyzed by using Intercooled Stata software
(Stata Corporation, College Station, TX, USA). Two-sided
Fisher’s exact test was executed to analyze possible associa-
tions of SNP rs12212067T>G in the FOXO3A gene with the
phenotype of severe malaria. The various genetic models
(dominant, recessive, allelic) were applied. Hardy-Weinberg
equilibria were tested using the random-permutation proce-
dure as implemented in the Arlequin v. 3.5.1.2 software
(Excoffier and Lischer 2010). The level of significance was
set to a P value of <0.05.
Results
The genotype frequency of SNP rs12212067T>G in the
FOXO3A gene was in Hardy-Weinberg equilibrium (HWE)
in the mild malaria subgroup. The cases groups significantly
departed from HWE. Genotype frequencies of cases and
controls are shown in Table 1. The genotype distribution
between cases and controls were also tested using a 2×3 test
for heterogeneity. A difference between the cases and controls
were observed (chi-square=15.89, df=2, P=0.0003). This
test establishes a difference between the cases and controls.
The frequency of the minor alleleG was 29 and 21 % in cases
and controls, respectively. This was also reflected when
looking at the genotypes, where TG occurred more frequently
among cases compared to controls (50 vs. 32 %). The associ-
ation of SNP rs12212067T>Gwith the severity of malaria was
reproducible in different genetic models. The allelic model
provided an association of the minor allele G with an in-
creased risk to severe malaria (OR=1.54, 95 % CI=1.15–
2.05, P=0.0028). The dominant model also showed a signif-
icant contribution of the minor allele G to severe malaria
(OR=1.94, 95 % CI=1.36–2.77, P=0.0002).
Discussion
The strong pressure of malaria in endemic areas has led to
selection of human genetic factors that are associated with
protection against severe malaria. However, little is known
about the prognosis of malaria severity. The distribution of the
genotype frequency of SNP rs12212067T>G in the FOXO3A
in severe malaria cases deviated from HWE. Nevertheless,
based on the genotyping technique of direct sequencing, sam-
pling procedure and characteristics of the study population,
we can exclude typing error and sampling bias. As the study
population has been recruited in a narrow area in Gabon,
population admixture is very unlikely. A diseased population
is expected not to conform with HWE when a true association
Table 1 Association of FOXO3A rs12212067T>G with severe malaria in Gabonese patients
FOXO3A rs12212067T>G Severe malaria n=297 (%) Mild malaria n=255 (%) OR (95 % CI) P value
Genotype
TT 138 (0.46) 160 (0.63) 1 Reference
TG 146 (0.5) 83 (0.32) 2.04 (1.4–2.95) 0.0001
GG 13 (0.04) 12 (0.05) 1.3 (0.5–3.1) NS
Allele
T 422 (0.71) 403 (0.79) 1 Reference
G 172 (0.29) 107 (0.21) 1.54 (1.15–2.05) 0.0028
Dominant
TT 138 (0.46) 160 (0.63) 1 Reference
GG + TG 159 (0.54) 95 (0.37) 1.94 (1.36–2.77) 0.0002
Recessive
TG + TT 284 (0.96) 243 (0.95) 1
GG 13 (0.04) 12 (0.05) 0.93 (0.38–2.27) NS
The P values were calculated using the two-sided Fisher’s exact test
NS not significant
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with the examined polymorphism exists. However, distribu-
tion of alleles according to HWE is expected, and present in
our study, in the control group (Zintzaras 2010). Another
study (Esser and Tomluk 2005) supported the fact that if
genotype distribution of the patient group shows deviation
from HWE, this may provide additional support for an asso-
ciation of the marker locus with the disease. Therefore, we
believe that the investigated SNP rs12212067T>G in the
FOXO3Amight be one of the signatures of negative selection
for severe malaria in the Gabonese population, while the
natural selection had been documented to play an important
role during malarial infection and in other infectious diseases
(Karlsson et al. 2014). Notably, our study may be seen as a
replication study, as it confirms the association described in
Kenyan and Vietnamese study groups (Lee et al. 2013).
During infection, Tregs play an important role in regulating
the clinical outcome of infectious diseases through their con-
trol of immune responses and their contribution to immune
homeostasis (Sakaguchi 2000, 2004). The maintenance of this
immune homeostasis is mediated by immunosuppressive cy-
tokines, including IL-10 and TGF-ß (Levings et al. 2002;
Taylor et al. 2006). This mediation appears to be modulated
strongly by the transcription factor FOXO3 (Dejean et al.
2009). Therefore, it is reasonable that any polymorphism in
the FOXO3A gene might modify immune responses and,
consequently, the prognosis of the disease.
With regard to FOXO3A variability, information on the
clinical outcome of inflammatory or infectious diseases is
scarce (Lee et al. 2013; Wang et al. 2014). In the present study,
we assessed the contribution of the intronic variant
rs12212067T>G of FOXO3A to the outcome of Plasmodium
falciparum malaria among Gabonese children. Our finding
suggests that FOXO3A is involved in the regulation of the
immune response during malaria. The minor allele G was
significantly associated with severe malaria, the complicated
form of the disease. This is in agreement with a previous study
where identical associations were observed in sizable study
groups from Vietnam and Kenya (Lee et al. 2013).
Many studies have indicated a role of FOXO3 in the
regulation of inflammatory cytokines (Dejean et al. 2009;
Litvak et al. 2012), although the relevance of such functions
in humans still remains unclear (Lee et al. 2013). The associ-
ation of the FOXO3A allele G with susceptibility to severe
malaria suggests an interference of this variant with human
inflammatory responses. In fact, it was shown that FOXO3
restricts the production of inflammatory cytokines in human
monocytes through the TGFß1 mechanism (Lee et al. 2013).
Thus, the explanation of how the minor allele G increases the
risk of severe malaria is based on the FOXO3-driven pathway
that confines the inflammatory responses in monocytes, which
through TGFß1, reduces the production of pro-inflammatory
cytokines including TNFα and increases the production of
anti-inflammatory cytokines such as IL-10 (Lee et al. 2013).
Our study provides information on the FOXO3 transcrip-
tion factor, in particular, regarding the contribution of
rs12212067T>G polymorphism in the regulation of the im-
mune response during Plasmodium falciparum malaria. With
allele frequencies of 25 % in the present study, 19 % in
African Americans, 25 % in the Luhya ethnic group from
Kenya, and 21% in Yoruba fromNigeria; the minor FOXO3A
allele rs12212067G appears to have reached stability in the
African populations studied or to be subjected to negative
selection, further reducing the occurrence of this allele.
Whether FOXO3A rs12212067G confers any advantage with
regard to other phenotypes needs to be studied.
Several limitations apply to our study. Although sufficient
statistical significance of our result was achieved and the
results are in agreement with previous findings in Kenyan
and Vietnamese studies, the study group is rather small.
Furthermore, as this finding of the rs12212067G association
was not confirmed in a recent genome-wide association study
on malaria (Timmann et al. 2012), the usefulness and validity
of candidate gene studies in general and in this study in
particular may be questioned. We believe, however, that in
polygenic diseases, all genetic contributions identified should
be considered in order to add to and eventually complete our
understanding of the genetic basis of infectious diseases.
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Abstract
Background
Current artesunate (ARS) regimens for severe malaria are complex. Once daily intramuscu-
lar (i.m.) injection for 3 d would be simpler and more appropriate for remote health facilities
than the current WHO-recommended regimen of five intravenous (i.v.) or i.m. injections
over 4 d. We compared both a three-dose i.m. and a three-dose i.v. parenteral ARS regimen
with the standard five-dose regimen using a non-inferiority design (with non-inferiority mar-
gins of 10%).
Methods and Findings
This randomized controlled trial included children (0.5–10 y) with severe malaria at seven
sites in five African countries to assess whether the efficacy of simplified three-dose regi-
mens is non-inferior to a five-dose regimen. We randomly allocated 1,047 children to
receive a total dose of 12 mg/kg ARS as either a control regimen of five i.m. injections of 2.4
mg/kg (at 0, 12, 24, 48, and 72 h) (n = 348) or three injections of 4 mg/kg (at 0, 24, and 48 h)
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either i.m. (n = 348) or i.v. (n = 351), both of which were the intervention arms. The primary
endpoint was the proportion of children with99% reduction in parasitemia at 24 h from
admission values, measured by microscopists who were blinded to the group allocations.
Primary analysis was performed on the per-protocol population, which was 96% of the
intention-to-treat population. Secondary analyses included an analysis of host and parasite
genotypes as risks for prolongation of parasite clearance kinetics, measured every 6 h, and
a Kaplan–Meier analysis to compare parasite clearance kinetics between treatment groups.
A post hoc analysis was performed for delayed anemia, defined as hemoglobin 7g/dl 7 d
or more after admission.
The per-protocol population was 1,002 children (five-dose i.m.: n = 331; three-dose i.m.:
n = 338; three-dose i.v.: n = 333); 139 participants were lost to follow-up. In the three-dose i.
m. arm, 265/338 (78%) children had a99% reduction in parasitemia at 24 h compared to
263/331 (79%) receiving the five-dose i.m. regimen, showing non-inferiority of the simplified
three-dose regimen to the conventional five-dose regimen (95% CI −7, 5; p = 0.02). In the
three-dose i.v. arm, 246/333 (74%) children had99% reduction in parasitemia at 24 h;
hence, non-inferiority of this regimen to the five-dose control regimen was not shown (95%
CI −12, 1; p = 0.24). Delayed parasite clearance was associated with the N86YPfmdr1 geno-
type. In a post hoc analysis, 192/885 (22%) children developed delayed anemia, an adverse
event associated with increased leukocyte counts. There was no observed difference in
delayed anemia between treatment arms.
A potential limitation of the study is its open-label design, although the primary outcome
measures were assessed in a blinded manner.
Conclusions
A simplified three-dose i.m. regimen for severe malaria in African children is non-inferior to
the more complex WHO-recommended regimen. Parenteral ARS is associated with a risk
of delayed anemia in African children.
Trial registration
Pan African Clinical Trials Registry PACTR201102000277177
Introduction
Studies to optimize artesunate (ARS) treatment regimens in malaria have been surprisingly
sparse, given that ARS is now established as the treatment of choice for severe malaria in both
adults and children [1,2]. WHO recommends ARS (2.4 mg/kg) administered by intravenous (i.
v.) or intramuscular (i.m.) routes at 0, 12, 24, 48, and 72 h after admission [2], although simpler
regimens would be preferable, assuming that safety and efficacy were not compromised [2].
The advantages of a simpler regimen are obvious to health care workers in under-resourced
settings, where finding and maintaining i.v. access in small, sick children to ensure that correct
doses are given on time is a challenge [1,3,4].
In an earlier study, a simplified three-dose ARS i.v. regimen was found to be non-inferior in
pharmacodynamic efficacy to the conventional WHO regimen [1], and its pharmacokinetics
(PK) were defined with a formulation that conformed to standards of good manufacturing
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practice. Since then, WHO has prequalified another formulation of ARS (Guilin Pharmaceuti-
cal, Shanghai, China), making it more widely used. We have also compared the i.v. and i.m.
routes of this product for severe malaria in African children and have described the PK of a
WHO-recommended dose regimen using ARS [4]. This regimen of one dose of 2.4 mg/kg fol-
lowed by four doses of 1.2 mg/kg has been superseded by a regimen of five doses of 2.4 mg/kg,
and there has since been debate about the simplified (once daily) i.v. regimen for severe malaria
[5,6]. The i.m. route has not yet been studied in adequately powered dose optimization trials.
We examined i.m. ARS in severe malaria in seven hospitals of the Severe Malaria in African
Children (SMAC) network [7,8]. We assessed whether splitting the total dose of 12 mg/kg into
a simplified once daily i.m. or i.v. three-dose regimen (4 mg/kg per dose) is non-inferior to the
WHO-recommended five-dose regimen (2.4 mg/kg per dose). We also examined associations
of genetic polymorphisms of pfmdr1 and kelch-13 with parasite clearance kinetics and, in post
hoc analysis, the occurrence of delayed anemia.
Our primary study objective was to assess the non-inferiority of i.v. ARS and i.m. ARS sim-
plified dosing regimens (4 mg/kg ARS at 0, 24, and 48 h; 12 mg/kg total dose) to the standard i.
m. treatment dosing regimen (2.4 mg/kg ARS at 0, 12, 24, 48, and 72 h; 12 mg/kg total dose) in
clearing parasitemia in African children with severe malaria. Our secondary study objectives
were to compare the tolerability and safety of the three ARS dosing regimens, to analyze host
and parasite genotypes as risks for prolongation of parasite clearance kinetics, measured every
6 h, and to compare parasite clearance kinetics between treatment groups. An exploratory
objective was to analyze genetic polymorphisms in humans and parasites linked to disease and
treatment, and a post hoc objective was to assess the occurrence of delayed anemia.
Methods
The trial was performed according to the principles of the Declaration of Helsinki and Good
Clinical Practice. Ethics committees and competent authorities for each study site approved
the study. A data monitoring board (DMB) provided oversight for the study with respect to
safety and efficacy as well as appropriate implementation of the defined stopping rules.
Study Design
This was an open-label, randomized, multicenter, parallel-group, three-arm study to compare
the antimalarial activity and safety of three ARS dosing regimens in children with severe Plas-
modium falciparummalaria. Patients (as shown in Fig 1) were randomly assigned to one of
three dosing regimens consisting of a total of 12 mg/kg parenteral ARS: (i) 2.4 mg/kg i.m. on
admission and at 12, 24, 48, and 72 h, (ii) 4 mg/kg i.m. on admission and at 24 and 48 h, and
(iii) 4 mg/kg i.v. on admission and at 24 and 48 h. Time points of administration of ARS for
each group are represented in Table 1.
Parasitemia was measured by thick blood smears at 6-h intervals and prior to the each dose
of treatment for at least 48 h following the first dose of study drug, or until three consecutive
negative smears were recorded within the last 24-h period. Thick blood films were also exam-
ined on days 7, 14, and 28.
The primary efficacy endpoint was the proportion of patients with99% parasite reduction
from the baseline asexual parasite count at 24 ± 1 h. Parasitemia was always quantitated before
the 24-h dose was administered, i.e., after either one (intervention arms) or two (control arm)
doses of ARS had been administered. This endpoint was derived from discussions in the
SMAC network and from our own studies [1,4] and is based on the following reasoning. First,
WHO guidelines for the treatment of severe malaria [9] are based on studies that have used
multiple outcomes. For efficacy, these are death, parasite clearance time, fever clearance time,
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time to discharge from hospital (days), and coma resolution time. As studies using mortality as
an endpoint are impracticable in seasoned centers where overall mortality from severe malaria
is<5%—requiring sample sizes that are too large—we have chosen a parasitemia clearance
parameter as an endpoint. Parasite clearance kinetics was also used when a quinine loading
dose (20 mg/kg salt, if no pretreatment) was being developed and compared with the then stan-
dard dose (10 mg/kg salt), when a mortality study comparing the two regimens was ruled out
on sample size grounds. Parasite clearance time was a crucial determinant of efficacy for com-
paring the same drug in two dosing regimens [10]. In severe malaria, clinically advantageous
benefits of more rapid clearance of parasites by ARS (even when given by suppository) have
been reported in comparison with i.m. artemether [11]. The 24-h time point was chosen as an
Fig 1. Trial profile. *These patients completed the study but were not included for the primary endpoint analysis because of protocol deviations. $These
patients completed the study but were not included for the primary endpoint analysis because of sampling issues. +These patients completed the study but
were not included for the primary endpoint analysis because of dosing issues. §Lost to follow-up includes patients who (i) withdrew consent (n = 8), (ii) moved
from the study area (n = 9), and (iii) were discharged from the study due to malaria infection on day 28 (n = 1), amongst a variety of other reasons.
doi:10.1371/journal.pmed.1001938.g001
Table 1. Dosing regimen of artesunate.
Group Route Dose 0 h 12 h 24 h 48 h 72 h
Five-dose i.m. i.m. 2.4 mg/kg X X X X X
Three-dose i.m. i.m. 4.0 mg/kg X X X
Three-dose i.v. i.v. 4.0 mg/kg X X X
doi:10.1371/journal.pmed.1001938.t001
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endpoint because most deaths (>60%) from severe malaria take place within 24 h of admission,
and accurate assessment of parasitemia becomes more difficult at later time points.
Evaluation of the whole regimens is included in the secondary outcome measures (and
there is no discrepancy between the results for this and the 24-h end point). Further endpoints
were time to total clearance of asexual parasites, time to 99% reduction of asexual parasites,
time to 90% reduction of asexual parasites, time to 50% reduction of asexual parasites, propor-
tion of patients with genotype-uncorrected adequate clinical and parasitological response on
day 28, percent reduction in asexual parasites from baseline at 24 h after initiation of random-
ized study drug, and percent reduction in asexual parasites from baseline at 48 h after initiation
of randomized study drug.
During the conduct of this study, several patients in the case series developed delayed hemo-
lytic anemia following ARS therapy, mostly in the second and third week from the start of ther-
apy [12–15]. Motivated by these events, we amended our trial protocol and undertook two
exploratory post hoc analyses of delayed anemia. In the first, all trial participants were screened
and treated for delayed anemia, defined as hemoglobin (Hb) 7 g/dl seven or more days after
admission. In the second, a subgroup of 72 patients in Kumasi and Lambaréné who underwent
detailed hematological monitoring for 28 d following discharge from the hospital were assessed
for hemoglobin and laboratory markers of hemolysis (such as lactate dehydrogenase) during
follow-up [16]. For the patients in the subgroup, we were able to assess laboratory markers of
hemolysis (such as lactate dehydrogenase) in more intensive follow-up, whereas the last day of
scheduled sampling for these particular markers for all other patients in the study was day 7.
Participants
Children were aged 6 mo to 10 y, with a diagnosis of P. falciparum infection (parasitemia
5,000 parasites/μl on initial blood smear) and clinical signs and symptoms severe enough to
require hospitalization, according to the SMAC definition of severe malaria that best reflects
the policies of African hospitals [7,8]. Most (87%) of these children also fulfilled one or more
criteria of the WHO definition of severe malaria [17], which include severe anemia (hematocrit
of<15% or Hb< 5 g/dl with a parasite density of>10,000/μl), hyperlactatemia (5 mmol/l),
hyperparasitemia (>250,000 parasites/μl), hypoglycemia (whole blood or plasma glucose
2.2 mmol/l), and hemoglobinuria (urine that is dark red or black, with a dipstick that is positive
for Hb/myoglobin).
In addition, children were required to be willing and able to comply with the study protocol
for the duration of the study, be willing to remain in the hospital for at least 3 d, and have had
written informed consent provided by their parents or guardians. Exclusion criteria included
known serious adverse reaction or hypersensitivity to artemisinins, any underlying disease that
might compromise the diagnosis and evaluation of the response to the study medication, par-
ticipation in any investigational drug study during the 30 d prior to screening, and adequate
(according to WHO and country-specific guidelines) antimalarial treatment within 24 h prior
to admission.
Patients were recruited at the Centre de Recherches Médicales de Lambaréné, Lambaréné,
Gabon (n = 245); Queen Elizabeth Central Hospital, Blantyre, Malawi (n = 211); the Université
des Sciences de la Santé, Libreville, Gabon (n = 150); the School of Medical Sciences at the Uni-
versity of Science and Technology (Komfo Anokye Teaching Hospital), Kumasi, Ghana (n =
149), Kenya Medical Research Institute Kondele Children’s Hospital, Kisumu, Kenya (n =
129); Edward Francis Small Teaching Hospital (former Royal Victoria Teaching Hospital),
Medical Research Council Laboratories, Banjul, The Gambia (n = 90); and the Kenya Medical
Research Institute Centre for Geographic Medicine–Coast, Kilifi, Kenya (n = 73).
Artesunate and Severe Malaria in Children
PLOSMedicine | DOI:10.1371/journal.pmed.1001938 January 12, 2016 5 / 22
A total of 45 participants were lost to follow-up between the time of randomization and the
primary endpoint analysis time point at 24 h. Loss to follow-up was due to death, withdrawal
of consent, protocol deviations, not receiving all doses, or sampling issues. Sampling issues
were defined as physical difficulties in obtaining blood due to the small size of participants and
difficulties with venipuncture. A total of 139 participants were lost to follow-up after the 24-h
primary endpoint analysis time point. Participants were considered lost to follow-up after the
24-h time point if they were unable to be reached when research staff tried to contact them at
least five times at two different times of day via telephone, and with at least two house visits,
within a 2-wk period.
Patient participation included hospitalization for at least 3 d and follow-up for at least 28 d
following the first dose of study drug. Participants had scheduled follow-up visits in the clinic
on days 7, 14, and 28, during which vital sign evaluation, physical examination, adverse event
(AE) review, and blood sampling for hematology, biochemistry, parasitological assessments,
PK analysis, and exploratory analyses were conducted
Randomization and Masking
Randomization was balanced at each study site in a 1:1:1 ratio for each regimen. Randomiza-
tion cards were supplied in numbered, sealed envelopes. The envelope for each participant was
opened after inclusion in the trial, directly before treatment initiation. Microscopists were not
informed about group allocations.
Procedures
ARS for injection (Artesun; Guilin Pharmaceutical, Shanghai, China) was supplied as powder
and reconstituted before injection. Artemether-lumefantrine was given at discharge in a weight-
normalized dosing regimen [18].
Other concomitant therapies were given according to published guidelines [2] and the stan-
dard operating procedures of the sites. Malarial infection recurring within 28 d was treated
with artemether-lumefantrine.
Malaria smears were done every 6 h until three consecutive negative smears were recorded
[19] and were read independently by two microscopists. Vital signs were recorded at least
twice daily, and physical examination was done repeatedly, over the period of hospitalization.
Population PK studies were performed on a subset (n = 288) of patients for the parent com-
pound ARS, the primary metabolite dihydroartemisinin (DHA) and the secondary metabolite,
the primary DHA glucuronide (DHAG), using established population PK techniques that were
refined using the results of the first dose optimization study [1]. PK data were available for 39
of the patients in the anemia analysis. Venous samples (400 μl) were collected 30, 60, 120, 240,
or 360 min after each of three dosings. Allocation to one of the five predefined sampling time
points was random within each treatment arm. Samples were stored at −80°C until use. ARS,
DHA, and DHAG concentrations were assayed using liquid chromatography/mass spectrome-
try [20]. In total, 851 samples were analyzed from three study centers (from 116 patients from
Lambaréné, 84 from Kisumu, and 88 from Kumasi). Parasite and host polymorphisms were
examined in the following genes using published methods and primers for PCR: pfmdr1, kelch-
13, the sickle cell gene, and the gene for glucose-6-phosphate dehydrogenase (G6PDH) [20,21].
This analysis was carried out on the subset of patients included in the PK analysis.
Statistical Analysis
Fisher’s exact test for one-sided equivalence [22] was used to assess treatment group differences
in parasite clearance for the per-protocol (PP) and intention-to-treat (ITT) populations, and
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the 95% CI of the difference in proportion is given. Primary analysis was on the PP population,
since it is more conservative in non-inferiority models. Testing was done hierarchically, with
comparisons of the two experimental arms (three-dose i.m. and three-dose i.v.) against the
control (five-dose i.m.), corrected for multiple testing using the Bonferroni method. Only
when both tests rejected the null hypothesis was a further test comparing the two experimental
arms planned. As secondary endpoints, parasite clearance times were calculated using Kaplan–
Meier estimates and a Cox model with treatment arm and study center as covariates, when not
otherwise described. Alpha< 0.05 was considered significant.
The needed sample size was calculated based on the results of our prior study [1,6]. We
assumed that 82% of patients would have a99% reduction in parasitemia at 24 h (primary
endpoint) and set power to 0.8, alpha to 0.05, and delta to 0.1. Using the Farrington and Man-
ning procedure [23] as implemented in the Design package of R v. 2.10.1, the calculated sample
size needed was 316 per arm when multiple comparisons between the groups were included.
The total estimated sample size needed, with 10% headroom for loss to follow-up, was there-
fore 1,044 participants.
The non-inferiority margin delta was pre-specified as an absolute difference of 10% for the
primary endpoint on the basis of our previous study [1] and published methods for analyzing
time-to-event outcomes [24]. For the Cox model, the non-inferiority margin was translated
into a hazard ratio (HR) assuming a 82% cure rate (99% reduction in parasitemia at 24 h)
with the control (five-dose i.m.) regimen and an at least 72% cure rate with the experimental
(three-dose i.m. and three-dose i.v.) regimens.
All patients who received at least one dose of the study drug were included in the safety
analysis. Delayed anemia was analyzed using a logistic regression model for non-hematological
variables, a two-way ANOVA for genotype analysis, and an ANCOVA for hematological
variables.
Descriptive statistics for the drug concentration data were calculated for the set of all
patients in this study who received the full dose of ARS and who had plasma concentration
data available. A population PK model, assuming 100% conversion of ARS to DHA, was devel-
oped using the nonlinear mixed-effects modeling software Phoenix NLME 1.2 (Pharsight,
St. Louis, Missouri, US). The final population PK models for ARS, DHA, and DHAG were eval-
uated using visual predictive checks. Plasma concentration over time data were described by a
one-compartment PK model with additive residual error and an exponential term for interpati-
ent variability. Initial PK parameter estimates were from our previous SMAC trial [1]. Route of
administration, study center, weight, age, height, delayed anemia, parasitemia, and host and
parasite genotypes were added as covariates in the model by stepwise forward inclusion. Model
improvement by covariates was statistically tested by the decrease in −2 log likelihood. The
final population PK model included all covariates associated with a significant increase in log
likelihood (5% significance).
Role of the Funding Source
The clinical sponsor of the trial was Universitätsklinikum Tübingen, and the corresponding
author P. G. K. acted as the sponsor’s representative. The corresponding authors had full
access to all of the data in the study and had final responsibility for the decision to submit for
publication.
Results
In all, 1,047 patients were randomized and received at least one dose of study drug, as shown
in Fig 1. This is the safety population and also defines the ITT population as all patients had
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P. falciparum infection. The PP population is defined as all patients from the ITT population
who received all doses of randomized study drug and for whom the primary endpoint could be
calculated. This is the primary analysis population for efficacy and is 96% of the ITT popula-
tion (n = 1,002).
Recruitment was from 4 July 2011 until 25 September 2012. As pre-specified in the protocol,
after 50 patients completed the trial procedures up to 72 h, all serious AEs (SAEs) including
deaths were reviewed by the DMB, with no findings that required stopping the study. After 100
patients completed the trial up to 24 h in each cohort, parasitemia evaluations were reviewed
by the DMB to confirm that in all cohorts, 99% reduction in parasitemia was achieved in at
least 60% of patients after 24 ± 1 h (stopping rule). After DMB reviews, there was no finding
to stop recruitment. There were to be ad hoc reviews if SAEs and/or deaths in one cohort
increased significantly compared with any other. For deaths in any cohort, the threshold to
trigger review by the DMB was 4% (stopping rule), but it was not invoked. Anemia was studied
in patients as shown in Fig 2. Table 2 summarizes the baseline demographic, clinical, and labo-
ratory variables of patients in the ITT population.
Figs 3 and 4 present evidence that the three-dose i.m. route for ARS is non-inferior to the
WHO-recommended five-dose i.m. regimen. Both i.m. routes had a higher proportion of
patients with99% reduction in parasitemia at 24 h (78%, or 265/338, for the three-dose i.m.
group and 79%, or 263/331, for the five-dose i.m. group) (by about 5%) than the three-dose i.v.
route (74%, or 246/333). This three-dose i.v. regimen had previously been found to be compa-
rable in efficacy to the WHO-recommended five-dose i.v. regimen [1]. Time to 99% parasite
clearance, specified as a secondary analysis, was comparable between treatment groups (Fig 5;
S1 Table). Since the Fisher’s exact test for one-sided equivalence does not account for stratify-
ing covariates, which may be anti-conservative, the robustness of the results was tested with
Cox proportional hazards models adjusted for study center, which showed non-inferiority
(lower confidence interval limit of the HR> 0.74) [24,25] for all comparisons (three-dose i.m.
versus five-dose i.m., HR 1.04 [97.5% CI 0.88–1.24]; three-dose i.v. versus five-dose i.m., HR
0.89 [97.5% CI 0.75–1.06]; three-dose i.m. versus three-dose i.v., HR 1.18 [95% CI 1.00–1.37]).
For the three treatment groups, the estimates of time to 90% parasite clearance, adjusted for
center and initial parasitemia, were significantly different (Fig 6). This difference can be attrib-
uted to a more rapid clearance in the three-dose i.m. group compared with the five-dose i.m.
group (HR 1.21 [95% CI 1.04–1.41]). In addition, no difference was seen in fever clearance
time between groups (S3–S5 Tables). No case required rescue treatment before discharge from
hospital, and 16 patients died, with no group differences. There were 41/885 (5%) patients who
were parasitemic at 28 d: 13 in the three-dose i.v. group, 11 in the three-dose i.m. group, and 17
in the five-dose i.m. group.
N86YPfmdr1 was found in 107/287 (37%) parasites and was associated with delayed time to
99% and 100% parasite clearance estimates of 2.8 h (95% CI 0.9–4.8 h; p = 0.005) and 4.8 h
(95% CI 1.9–7.6 h; p< 0.001), respectively. No other N86YPfmdr1 polymorphisms (Y184F,
S1034C, N1042D, and D1246Y), including increased gene copy number of pfmdr1 (found in
13 samples, 5%), were associated with time to parasite clearance. There were no previously
reported polymorphisms in kelch-13 sequences (M476I, Y493H, R539T, I543T, and C580Y).
Tests of associations between parasite genotypes and clearance time estimates were corrected
for center and treatment group.
Drug detection was linear, with ranges of 1–2,500 nM, 165–16,500 nM, and 4–10,000 nM
for ARS, DHA, and DHAG, respectively. In total, 851 samples from 288 patients (153 male and
135 female, aged 0.5 to 10 y, mean 3.8 y) were analyzed: 92, 99, and 97 patients received the
five-dose i.m., three-dose i.m., and three-dose i.v. regimens, respectively. The population esti-
mates of PK parameters of the base models are presented in Table 3. These data confirm that
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the three regimens studied are comparable in their PK parameters, with the exception of a
larger volume of distribution of DHA following i.m. injection. In particular, estimates of time
to clearance were comparable between groups. Fig 7 presents plots of observed concentration–
time profiles for ARS, DHA, and DHAG according to treatment regimen. Estimated popula-
tion mean PK profiles are shown by the red lines. Interestingly, ARS plasma concentrations
varied more after i.v. than after i.m. administration. Study center, age, sex, weight, parasitemia,
and delayed anemia were considered as covariates. Of these covariates, parasitemia influenced
volume of distribution after i.v. ARS only, while the strongest influence was seen for study cen-
ter on volume of distribution/bioavailability and clearance of ARS (i.m.), DHA, and DHAG.
The occurrence of laboratory and clinical AEs and SAEs (Table 4) was similar in the three
groups. Out of 75 SAEs, 14 (five severe anemia, six persistent fever, two vomiting, and one
cough) were judged as possibly related to the study drug.
Fig 2. Post hoc analyses of patients with anemia. The right hand side of the diagram (in red) shows patients included in the substudy.
doi:10.1371/journal.pmed.1001938.g002
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During the conduct of this trial, a series of case reports described delayed hemolytic anemia
in travelers after receiving artemisinins [26] and prompted an urgent evaluation of the risk of
delayed hemolysis in a subset of our patients in Kumasi and Lambaréné, in whom detailed
hematological monitoring after discharge was possible, as an amendment to the protocol [16].
For these patients, we defined delayed hemolysis as the coexistence of (i) low haptoglobin
(<0.30 mg/dl) on day 14, (ii) any decrease in hemoglobin between days 7 and 14, and (iii) any
increase in lactate dehydrogenase between days 7 and 14 leading to a lactate dehydrogenase
level of over 350 U/l on day 14.
This substudy identified five out of 72 evaluable patients with anemia between days 7 and
28 [16]. In a post hoc analysis, we also included anemia detected by hemoglobin measurement
Table 2. Patient clinical and laboratory findings on admission in intention-to-treat population.
Variable Arm Total (n = 1,047)
Three-Dose i.v. (n = 351) Three-Dose i.m. (n = 348) Five-Dose i.m. (n = 348)
Clinical ﬁndings
Female 162 (46%) 166 (48%) 168 (48%) 496 (47%)
Male 189 (54%) 182 (52%) 180 (52%) 551 (53%)
Age, y 4.0 (2.4) 4.1 (2.5) 4.2 (2.5) 4.1 (2.5)
Aged 0–3 y 201 (57%) 185 (53%) 185 (53%) 571 (54%)
Aged 4–7 y 122 (35%) 132 (38%) 130 (37%) 384 (37%)
Aged >8 y 28 (8%) 31 (9%) 33 (10%) 92 (9%)
Pulse, beats/minute 134 (26) 133 (25) 133 (25) 133 (25)
Respirations/minute 40 (13) 39 (11) 40 (13) 40 (12)
Temperature, °C 38.2 (1.2) 38.1 (1.2) 38.1 (1.2) 38.1 (1.2)
Weight, kg 14.3 (5.3) 14.3 (5.0) 14.8 (5.1) 14.4 (5.5)
Laboratory ﬁndings
Parasitemia per microliter × 10−3* 129.0 (4.6–2,965.0) 114.0 (5.0–1,439.0) 119.0 (4.1–2,675.0) 121.0 (4.1–2,965.0)
Hb, g/dl 8.5 (2.4) 8.7 (2.3) 8.7 (2.4) 8.6 (2.4)
White blood cell count, 103/μl 10.3 (5.5) 10.1 (5.2) 9.7 (4.6) 10.0 (5.1)
Neutrophils, 103/μl 5.5 (3.2) 5.3 (3.0) 5.4 (3.3) 5.4 (3.2)
Platelet count, 103/mm3 115 (117) 107 (108) 123 (130) 115 (119)
Clinical signs of severe malaria
Severe anemia 34 (10%) 42 (12%) 40 (11%) 116 (11%)
Hyperlactatemia 21 (6%) 18 (5%) 23 (7%) 62 (6%)
Hyperparasitemia 103 (29%) 91 (26%) 103 (30%) 297 (28%)
Hypoglycemia 13 (4%) 7 (2%) 18 (5%) 38 (4%)
Jaundice 28 (8%) 29 (8%) 25 (7%) 82 (8%)
Hemoglobinuria 6 (2%) 6 (2%) 7 (2%) 19 (2%)
Respiratory distress 30 (9%) 35 (10%) 28 (8%) 93 (9%)
Severe vomiting 25 (7%) 36 (10%) 26 (7%) 87 (8%)
Prostration 169 (48%) 160 (46%) 140 (40%) 469 (45%)
Cerebral malaria 32 (9%) 28 (8%) 23 (7%) 83 (8%)
Generalized seizures 39 (11%) 44 (13%) 28 (8%) 111 (11%)
Data are given as mean (standard deviation) or n (percent), except for parasitemia per milliliter, which is given as geometric mean (range). Clinical
classiﬁcation was according to the following deﬁnitions: severe anemia (hematocrit of <15% or Hb < 5 g/dl with a parasite density of >10,000/μl),
hyperlactatemia (5 mmol/l), hyperparasitemia (>250,000 parasites/μl), hypoglycemia (whole blood or plasma glucose  2.2 mmol/l), and hemoglobinuria
(urine that is dark red or black, with a dipstick that is positive for Hb/myoglobin).
*PP population.
doi:10.1371/journal.pmed.1001938.t002
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on day 7 or later. This increased the total number of patients with anemia (Hb 7 g/dl) a week
or more after the start of therapy to 192, although most were detected on day 7 due to sampling
bias, as the last scheduled blood sampling per protocol in our study was day 7. We also investi-
gated the AEs in all our patients (including those reported earlier [16]) by assessing anemia
at passive follow-up after day 7, and detailed information is given in Table 5. This analysis
includes the 72 patients from our earlier reported substudy [16].
We examined the relationships between other hematological variables, parasitemia, and
delayed anemia, and allowed for admission values by including these in covariance analysis of
the full dataset. There was no significant association between delayed anemia and admission
parasitemia (p = 0.30) or platelet counts on day 7 (p = 0.11). A significant association emerged
with leukocyte count (p< 0.001) and neutrophil count (p< 0.001) on day 7. Those with
delayed anemia had higher leukocyte (Fig 8) and neutrophil counts than those without delayed
anemia, regardless of the definition applied for delayed anemia.
G6PDH-deficient participants (A−) had more anemia on admission (odds ratio 4.3 [95% CI
2.1–9.0], p< 0.001) than those with G6PDH non-deficient genotypes, but this relationship did
not hold for delayed anemia (odds ratio 1.4 [95% CI 0.6–3.2]). HbAC or HbAS genotype was
not associated with delayed anemia, and there was no relationship between delayed anemia
and PK parameters.
Discussion
This study consolidates previous work aiming to optimize dosage regimens using parenteral
ARS for severe malaria [1]. Here, simpler three-dose i.m. and i.v. regimens have been compared
Fig 3. Per-protocol population primary endpoint analysis. PP treatment difference in proportions of
patients with99% parasite reduction, with corresponding 95% confidence intervals. The vertical line
indicates the non-inferiority margin (δ). The three-dose i.m. treatment group is non-inferior to the five-dose i.
m. treatment group (p = 0.02), whereas the three-dose i.v. group is not non-inferior (p = 0.24). Note that the p-
value is calculated using Fisher’s exact test for one-sided equivalence under the assumption that both
regimens are equally efficacious.
doi:10.1371/journal.pmed.1001938.g003
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to the WHO-recommended five-dose i.m. regimen. This study provides new insights into ARS
PK, delayed anemia, and genetic markers of delayed parasite clearance. Our studies used the
pharmacodynamic endpoint of parasite clearance rather than other clinical outcome measures
such as mortality because the latter requires impracticably large studies (as debated [5,6]). In
comparing the same drug given in different doses and by different routes, parasite clearance
kinetics should accurately reflect differences in in vivo antiparasitic activity because the
mechanism of action is the same. It follows that if there are no differences in parasite clearance
kinetics between treatments, then they can be considered to be of comparable efficacy. For
uncomplicated malaria, for example, inadequate oral dosing with ARS is associated with pro-
longed parasite clearance kinetics, and in severe malaria a loading dose of quinine significantly
shortened parasite clearance times compared with a non-loading-dose regimen [10,26].
From our previous study, we concluded that a simplified once daily regimen was non-infe-
rior in efficacy to the conventional i.v. ARS dosing regimen [1]. This study establishes that the
once daily i.v. is not consistently non-inferior to the three-dose and five-dose i.m. regimens.
There are several corollaries to this observation. First, clearance kinetics with i.v. once daily
ARS in this study (74% achieved99% clearance from baseline at 24 h) is very similar to the
previous result of 76% with i.v. once daily ARS. This latter result was also comparable to the
five-dose WHO-recommended i.v. regimen in that smaller study and points to a preference for
the i.m. route because it is associated with faster clearance kinetics (Figs 5–7). Second, these
results confirm that the endpoint chosen is both robust and pharmacodynamically sensitive as
a measure of ARS antimalarial efficacy. Also, a once daily simplified i.m. regimen is of compa-
rable efficacy to the five-dose WHO-recommended i.m. regimen, a finding that was robust
Fig 4. Intention-to-treat population primary endpoint analysis. ITT treatment difference in proportions of
patients with99% parasite reduction, with corresponding 95% confidence intervals. The vertical line
indicates the non-inferiority margin (δ). The three-dose i.m. treatment group is non-inferior to the five-dose i.
m. treatment group (p = 0.02), whereas the three-dose i.v. group is not non-inferior (p = 0.24). Note that the p-
value is calculated using Fisher’s exact test for one-sided equivalence under the assumption that both
regimens are equally efficacious.
doi:10.1371/journal.pmed.1001938.g004
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when analyzed using different statistical methodologies. This finding has important implica-
tions for practice. The i.m. route for administration of antimalarials is preferable to the i.v.
route in small children [27]. Analysis of secondary endpoints of parasite clearance supports the
results of the primary endpoint analysis, and suggests that the once daily i.m. regimen has an
even faster time to 90% parasite clearance than the conventional i.m. regimen (median 12 ver-
sus 18 h; Figs 5 and 6; S1 Table).
The frequently observed N86YPfmdr1 polymorphism has previously been associated with
increased sensitivity to artemisinin in in vitro assays in Senegal [28] and decreased sensitivity
to artemether in Nigeria [29], with no effect in Thai isolates [30]. Our results provide in vivo
evidence for decreased sensitivity to ARS (DHA) of parasites with N86YPfmdr1. Changes in the
frequencies of polymorphisms in pfmdr1 are clearly worth monitoring in future epidemiologi-
cal studies. High unadjusted cure rates (95%) in our patients may reflect the large artemisinin
(24 mg/kg total dose of ARS and artemether) component of the treatment course and efficacy
of the combination partner (lumefantrine).
Fig 5. Kaplan–Meier plot for time to 99% parasite clearance in the per-protocol population. Time to 99% parasite clearance under parenteral ARS
treatment is shown. Using the 10% delta at 24 h, both three-dose regimens are non-inferior to the five-dose regimen in a Cox proportional hazards model.
The PP population has been used for the secondary endpoints.
doi:10.1371/journal.pmed.1001938.g005
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The results of our population PK analysis are consistent with classical and previous popula-
tion PK studies on parenteral ARS [4,6], including in Tanzania [31]. A suggestion, based on
modeling, that doses higher (~3 mg/kg per dose for children<10 kg) [31] than currently rec-
ommended by WHOmay be needed for smaller children is obviated if our higher dose (4 mg/
kg) and simpler regimen is implemented. As noted previously, there was no relationship
Fig 6. Kaplan–Meier plot for time to 90% parasite clearance in the per-protocol population. Time to 90% parasite clearance under parenteral ARS
treatment is shown. Using the 10% delta at 24 h, both three-dose regimens are non-inferior to the five-dose regimen in a Cox proportional hazards model.
The PP population has been used for the secondary endpoints.
doi:10.1371/journal.pmed.1001938.g006
Table 3. Population pharmacokinetic analysis of parenteral artesunate in severemalaria.
Arm Drug Metabolite Volume of Distribution (Liters) (95% CI) Clearance (Liters/Hour) (95% CI)
Three-dose i.v. ARS 32.0 (22.3–41.6) 42.0 (28.9–55.1)
DHA 12.0 (10.2–13.8) 9.9 (8.4–11.3)
DHAG 36.6 (32.0–41.3) 10.8 (9.0–12.7)
Three-dose or ﬁve-dose i.m ARS 21.1 (18.2–24.0) 33.3 (29.5–37.1)
DHA 25.3 (22.4–28.2) 8.5 (7.4–9.5)
DHAG 66.5 (58.2–74.8) 10.1 (8.3–11.9)
doi:10.1371/journal.pmed.1001938.t003
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between PK parameters and efficacy. We also present, to our knowledge for the first time, an
analysis of the glucuronide derivative of DHA (Fig 7; Table 3). This is quantitatively the most
important primary metabolite of DHA. Although it has poor antimalarial activity (IC50 of
DHAG = 5.7 μM, mean of two experiments), DHAG plasma concentrations commonly peaked
above 5 μM (Fig 7), rendering a contribution to parasite clearance possible. Repeated dosing
with ARS, in any regimen, does not show evidence of accumulation (Fig 7). This analysis also
allows us to examine other potential mechanisms for toxicity, which hitherto has not been
possible.
During the conduct of our trial a series of case reports appeared about delayed anemia in
travelers who had received parenteral ARS. Therefore, we amended the study protocol to address
Fig 7. Population pharmacokinetic profiles of artesunate, dihydroartemisinin, and dihydroartemisinin glucuronide. Plots of observed concentration–
time profiles for ARS and its major metabolites, DHA and DHAG, are presented according to treatment regimen. Estimated population mean PK profiles are
shown by red lines. The three columns of results for each regimen represent the findings after each dose.
doi:10.1371/journal.pmed.1001938.g007
Table 4. Serious adverse events in the intention-to-treat population.
SAE Outcome Arm Total
Three-Dose i.v. Three-Dose i.m. Five-Dose i.m.
SAEs 26 28 21 75
SAEs with a possible relationship to study drug 5 (19%) 3 (11%) 6 (29%) 14
SAEs with no relationship to study drug 21 (81%) 25 (89%) 15 (71%) 51
Deaths 6 6 4 16
Neurological sequelae after study completion (day 28) 3 1 4
Data are given as n or n (percent).
doi:10.1371/journal.pmed.1001938.t004
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the occurrence of delayed hemolytic anemia in our ongoing study. We identified delayed anemia
after ARS treatment using a small subgroup of patients from the current study [16] in whom it
was possible to study anemia defined by several criteria (low haptoglobin, elevated lactate dehy-
drogenase level, decrease inHb, exclusion of sickle cell disease and G6PDH deficiency). Secondly,
in a post hoc analysis that included the whole study population, we defined delayed anemia as
Hb 7 g/dl 7 d or more after admission. We confirmed the occurrence of delayed anemia in a
significant proportion (22%) of African children by using this simplified definition that may
therefore have greater practical utility. This definition of anemia does not reveal any
Table 5. Anemia occurrences from day 7 until day 28.
Anemia Outcome Number of Patients
Total patients with at least one late anemia episode 192 out of 885 followed up until day 28
Hb  7 g/dl on day 7 185 out of 972 followed up until day 7
Hb  7 g/dl on day 28 7
Late transfusion (> day 7) 4
Anemia on active follow-up (substudy) 5
doi:10.1371/journal.pmed.1001938.t005
Fig 8. Association between delayed anemia and increased white blood cell count at day 7. Individual
white cell counts (WBC) on day 7 (D7) are presented as medians and interquartile ranges, divided into those
who developed delayed anemia (12.8 × 103/μl, interquartile range 9.6–17, n = 186) and those who did not
(10.1 × 103/μl, interquartile range 8.1–12.4, n = 689). Patients with delayed anemia had a significantly higher
white blood cell count at day 7 (p < 0.001).
doi:10.1371/journal.pmed.1001938.g008
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relationships with PK parameters for ARS, DHA, or indeed DHAG. Instead, a higher leucocyte
(Fig 8) and neutrophil count at day 7 is associated with delayed anemia, suggesting that if ARS is
the cause of anemia, the mechanism does not involve bone marrow toxicity, because ARS can
cause dose-dependent neutropenia [25]. In a recent study of 60 travelers treated with ARS for
severe malaria, 13/66 (22%) had delayed anemia, which compares well with our findings. In this
study, pitting was significantly associated with delayed anemia [32]. Pitting is a process whereby
dead early-stage parasites are removed from erythrocytes by the spleen. Pitting may contribute
to the pathophysiology of delayed anemia, which is associated with markers of delayed hemoly-
sis, although available findings from AQUAMAT do not support this [33]. In the AQUAMAT
study, the incidence of post-admission severe anemia (Hb< 50 g/l) was comparable in the qui-
nine (5.7%) and ARS (4.6%) groups [34], and both groups had identical proportions of patients
(55%) receiving blood transfusions. It is unfortunate that only neurological sequelae were moni-
tored after discharge in the AQUAMAT study, as the risks of delayed anemia with ARS com-
pared to quinine could have been quantified in this cohort.
Weaknesses of this study are its open-label design, which may introduce biases in outcome
variables, although allocation bias was minimized and the primary outcome measures of para-
site clearance were assessed in a blinded way. The primary analysis at 24 h was before the full
treatment regimens had been completed, which may appear as a study limitation unless all par-
asite clearance estimates are also considered. Additionally, delayed anemia was first described
in travelers—and could therefore be addressed—only after the study was mostly complete. It
was studied in detail in 72 patients [16], with the remaining analysis being performed post hoc.
As there was no comparator arm using a drug other than ARS, further studies will be needed to
clarify the impact of artemisinins on delayed anemia. Some colleagues outside the SMAC net-
work may argue that mortality needs to be an endpoint in a study with severe malaria. How-
ever, our studies show that case fatality rates in severe malaria trials performed following
principles of good clinical practice should not exceed 5%, but rather be between 1% and 2%,
regardless of whether the WHO definition or our SMAC definition of cases is used [35]. Thus,
death as an endpoint is precluded by sample size requirements.
Simplifying ARS usage with a once daily i.m. regimen in severe malaria is supported by
our results, but because delayed anemia is common, patients should be monitored for this
complication.
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Editors' Summary
Background
Globally, about 200 million cases of malaria—a mosquito-borne parasitic disease—occur
every year. Malaria infections, which can be caused by several parasites, can be “uncompli-
cated” or “severe.” Prompt treatment of uncomplicated malaria, which presents with flu-like
symptoms, is essential to prevent the development of severe malaria. TheWorld Health
Organization (WHO) recommends artemisinin combination therapy (ACT) for the first-
line treatment of uncomplicated malaria in countries where the disease is always present. In
ACT, artemisinin derivatives (fast-acting antimalarial drugs that are cleared rapidly from
the body) are combined with a slower-acting, more slowly eliminated partner drug to pre-
vent the original infection recurring and to reduce the risk of the malaria parasites becoming
resistant to either drug. Severe malaria, which is usually caused by Plasmodium falciparum,
is characterized by anemia and by damage to the brain and other organs. Severe malaria kills
more than 400,000 people (mainly young children living in sub-Saharan Africa) every year.
WhyWas This Study Done?
WHO recommends that severe malaria be treated with intravenous or intramuscular injec-
tions of artesunate, a parenteral (injectable) form of artemisinin; patients with severe
malaria cannot take pills reliably or safely. Specifically, WHO recommends that patients be
given 2.4 mg of artesunate per kilogram of body weight intravenously or intramuscularly at
the time of admission (0 hours) and at 12, 24, 48, and 72 hours (followed by ACT to ensure
full parasite clearance). But this five-dose regimen is complex. A simpler regimen would be
easier to administer in resource-limited settings, where giving the correct doses on time to
small, sick children can be challenging. In this open-label, non-inferiority randomized con-
trolled trial (RCT), the researchers investigate the efficacy of a three-dose artesunate regi-
men for the treatment of severe malaria in African children. RCTs compare outcomes in
people randomly chosen to receive different interventions; in an open-label RCT, both the
researchers and the participants know which treatment is being given; a non-inferiority
trial investigates whether one treatment is not worse than another treatment.
What Did the Researchers Do and Find?
The researchers randomly allocated 1,047 children aged six months to ten years with severe
malaria attending seven clinical centers in five African countries to receive a total dose of
12 mg of artesunate per kilogram of body weight as five intramuscular injections of 2.4 mg/
kg given at 0, 12, 24, 48, and 72 hours (the control regimen) or as three intramuscular or
intravenous injections of 4 mg/kg given at 0, 12, and 24 hours (three-dose intramuscular
and intravenous regimens, respectively). The trial’s primary endpoint was the proportion
of children whose parasitemia (parasite count in the blood) at 24 hours was1% of that at
admission (in other words,99% parasite clearance). Among the 1,002 children who
received the planned drug doses (the per-protocol population), 78% in the three-dose intra-
muscular group had99% parasite clearance compared to 79% in the five-dose intramus-
cular group, a result that met a preset criterion for non-inferiority at 24 hours of the three-
dose intramuscular regimen to the control regimen. However, because only 74% of the chil-
dren in the three-dose intravenous group had99% parasite clearance, this regimen was
not shown to be non-inferior to the conventional five-dose regimen.
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What Do These Findings Mean?
These findings when combined with the findings of several secondary analyses suggest
that, in African children, a three-dose intramuscular artesunate regimen is non-inferior to
the WHO-recommended regimen for the treatment of severe malaria. The study’s open-
label design may limit the accuracy of its findings, as may its use of a primary endpoint
midway through drug treatment rather than at the end (the researchers note that 60% of
deaths from severe malaria occur during the first 24 hours of illness and that parasitemia
is harder to measure later during treatment) and its use of parasite clearance rather than
death as the primary endpoint (case fatality rates in severe malaria treatment trials are
very low, so a much larger study would be needed if death were used as the primary end-
point). Overall, these findings support the use of the three-dose intramuscular artesunate
regimen for the treatment of severe malaria. Importantly, however, 22% of the children in
the study developed delayed anemia, irrespective of treatment regimen. Thus, although
further studies are needed to clarify whether treatment with artesunate or the malaria
infection itself was responsible for the delayed anemia, patients treated with artesunate for
severe malaria should be routinely monitored for this complication.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1001938.
• Information is available from the World Health Organization on malaria (in several lan-
guages); theWorld Malaria Report 2014 provides details of the current global malaria
situation, including information on malaria in individual African countries; WHO’s
Guidelines for the Treatment of Malaria and itsManagement of Severe Malaria: A
Practical Handbook are available
• The US Centers for Disease Control and Prevention provides information on malaria
(in English and Spanish), including personal stories about malaria
• The UK National Health Service Choices website also provides information about
malaria, including a personal story
• Information is available from the Roll Back Malaria Partnership on the global control of
malaria
• The Scientists Against Malaria collaboration applies modern drug design and modeling
techniques to develop new treatments against malaria; its website includes information
about many aspects of malaria
• Public Health England provides a collection of guidance and research and analysis on
malaria
• MedlinePlus provides links to additional information on malaria (in English and
Spanish)
• More information about this trial is available
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Glucose-6-phosphate dehydrogenase 
deficiency and reduced haemoglobin levels 
in African children with severe malaria
Christian N. Nguetse1, Christian G. Meyer1,2, Ayola Akim Adegnika1,3, Tsiri Agbenyega4,5, Bernhards R. Ogutu6, 
Peter G. Kremsner1,3 and Thirumalaisamy P. Velavan1,2,7*
Abstract 
Background: Extensive studies investigating the role of host genetic factors during malaria associate glucose-
6-phosphate dehydrogenase deficiency with relative protection. G6PD deficiency had been reported to associate 
with anti-malarial drug induced with haemolytic anaemia.
Methods: A total of 301 Gabonese, Ghanaian, and Kenyan children aged 6–120 months with severe malaria recruited 
in a multicentre trial on artesunate were included in this sub-study. G6PD normal (type B), heterozygous (type A+) and 
deficient (type A−) genotypes were determined by direct sequencing of the common African mutations G202A and 
A376G. Furthermore, multivariate analyses were executed to associate possible contributions of G6PD deficiency with 
baseline haemoglobin levels, parasitaemia and with severe malarial anaemia.
Results: Two hundred and seventy-eight children (132 females and 146 males) were successfully genotyped for 
G6PD variants. The overall prevalence of G6PD deficiency was 13 % [36/278; 3 % (4/132) female homozygous and 
22 % (32/146) male hemizygous], 14 % (40/278) children were female heterozygous while 73 % (202/278) were G6PD 
normal [67 % (88/132) females and 78 % (114/146) males] individuals. Multivariate regression revealed a significant 
association of moderately and severely deficient G6PD genotypes with haemoglobin levels according to the baseline 
data (p < 0.0001; G6PD heterozygous: p < 0.0001; G6PD deficient: p = 0.009), but not with severe malarial anaemia 
(p = 0.66). No association of G6PD genotypes with baseline parasitaemia.
Conclusions: In this study, moderately (type A+) and severely (type A−) G6PD deficiency showed significant asso-
ciation with lower haemoglobin concentrations at baseline in African children with severe malaria without leading 
to severe malarial anaemia. In addition, there was no association of G6PD variant types with parasite densities on 
admission.
Keywords: Glucose-6-phosphate dehydrogenase deficiency, African children, Severe malaria
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Background
Malaria remains a major health problem, with approxi-
mately 3.2 billion people at risk. In 2015, WHO reported 
approximately 214 million cases and about 438,000 
deaths occurring in the world with the highest morbidity 
and mortality rates observed in Africa, especially among 
children under 5 years of age [1]. The control of the dis-
ease particularly in low transmission settings is the key 
target for malaria elimination [2] but such success is still 
a great challenge [3]. One approach to reduce the disease 
incidence is to block the transmission. Primaquine, a 
8-aminoquinoline effective for both transmission block-
ing of Plasmodium falciparum and anti-relapse treatment 
against Plasmodium vivax has been recommended for 
many years by the World Health Organization (WHO) 
[4, 5]. However, primaquine has a major drawback which 
limits its widely use. The drug is known to cause acute 
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haemolytic anaemia in individuals with glucose-6-phos-
phate-dehydrogenase (G6PD) deficiency [6, 7].
G6PD is a key enzyme catalysing the first reaction in 
the pentose phosphate pathway and provides a reduced 
form of nicotinamide adenine dinucleotide phosphate 
(NADPH) to help cells to counterbalance oxidative stress 
[8]. G6PD deficiency is a common, X-linked hereditary 
enzyme deficiency affecting approximately 400 million 
people worldwide [9], mainly in malaria-endemic regions 
[10]. Among the 186 mutations identified until 2012 in 
the G6PD gene [11], the variants 376A (G6PD type B), 
376G (G6PD deficiency type A+ and 202A (severe G6PD 
deficiency type A−) are the most common ones. The defi-
ciency types A+ (moderately deficient) and A− (severely 
deficient) constitute up to 90  % of reported G6PD vari-
ants [8, 12, 13]. Other mutations such as A542T, G680T 
or T968C have also been identified in parts of Africa 
and been suggested to contribute to G6PD deficiency. 
However, information available on these mutations is 
very scarce. For example, the T968C mutation has been 
reported to be common only in The Gambia [14] and 
Senegal [15]. Although, G6PD diagnostic enzyme tests 
are available, they are currently not widely used in most 
clinical studies, particularly because primaquine, is not 
regularly used in Africa. Any attempts to control malaria 
need to take into account also tertian malaria, which, 
although occurring rarely only in many parts of Africa, 
contributes to the world-wide malaria burden.
Previous case–control studies have reported an asso-
ciation of G6PD deficiency, in particular of the 202A 
variant, with an increased risk of severe malarial anaemia 
and a protection or reduced risk against cerebral malaria 
[16, 17]. Therefore, it is interesting to assess the influence 
of this allele on the clinical presentation of severe malaria 
among the African children recruited into this study.
This study was a sub-study of a multicentre trial of 
artesunate conducted by the “Severe Malaria in Afri-
can Children” (SMAC) consortium which assessed the 
non-inferiority of a simplified 3-dose regimen of intra-
muscular and intravenous artesunate [18]. The aim was 
to determine using direct sequencing the frequency dis-
tribution of G6PD deficiency in malaria children from 
Africa. Some exploratory analyses have also been per-
formed to investigate the effect of G6PD genotypes on 
asexual parasitaemia, haemoglobin concentrations and 
severe malarial anaemia during admission.
Methods
Study design and participants
This study was a sub-study of the SMAC follow-up 
study. The SMAC study was an open-label, randomized, 
multicentre (Gabon, Malawi, Ghana, Kenya, and The 
Gambia), parallel-group, three-arm study to compare 
the anti-malarial activity and safety of three artesunate 
(ARS) dosing regimens in children with severe P. falci-
parum malaria. Patients were randomly assigned to one 
of three dosing regimens consisting of a total of 12 mg/
kg parenteral ARS: (i) 2.4 mg/kg intramuscular on admis-
sion and at 12, 24, 48 and 72 h, (ii) 4 mg/kg intramuscular 
on admission and at 24 and 48 h, and (iii) 4 mg/kg intra-
venous on admission and at 24 and 48 h post admission. 
Parasitaemia was assessed by thick blood smears at 6  h 
intervals and prior to the each dose of treatment for at 
least 48 h following the first dose of study drug. Malaria 
occurs holoendemically and transmission rates in all 
study countries are high and perennial.
The present study involved participants of the SMAC 
study from Gabon, Ghana and Kenya. Three hundred and 
one children aged 6–120  months with a diagnosis of P. 
falciparum infection (parasitaemia  ≥5000 parasites/µL 
on initial blood smear) made using an alternative to con-
ventional thick film examination (Lambaréné method) 
[19] were randomly selected from the SMAC follow-up 
study [18]. Blood samples (400 μL) from all participants 
were collected in heparinized tubes. Specimens were 
stored at −80 °C for subsequent molecular analyses.
Ethics statement
The study was conducted in accordance with Good 
Clinical Practices, and approved by authorities for each 
study site (the Regional Ethics Committee in Lambaréné 
(CERIL) for Gabon, Committee on Human Research, 
Publication and Ethics, Kwame Nkrumah University of 
Science and Technology (KNUST), Kumasi, for Ghana 
and the National Ethics Research Committee, Kenya 
Medical Research Institute (KEMRI) for Kenya). Chil-
dren were enrolled into this study if a parent or guard-
ian was willing to provide written informed consent in 
accordance with local practice.
G6PD genotyping
Genomic DNA was isolated using QIAamp DNA mini 
blood kit (Qiagen, Hilden, Germany). A 968  bp frag-
ment of the G6PD gene containing the polymorphisms 
202G  >  A and 376A  >  G was amplified by PCR using 
primers 5′-GCCCCTGTGACCTCCCGCCA-3′ (for-
ward) and 5′-GCAACGGCAAGCCTTACATCTGG-3′ 
(reverse). The main focus was directed only to these two 
variants although some other deficient genetic mutations 
such as A542T (Senegal 1 %, The Gambia 2.2 %), G680T 
(The Gambia 0 %, Senegal 0 %) and T968C (The Gambia 
7.8 %, Senegal 10 %) have been reported at a substantially 
lower prevalences only [14, 15], and might have been 
present in this study population. However, they seem 
not to be responsible for the prevalence of G6PD defi-
ciency in all parts of Africa [20]. Briefly, 10 ng of genomic 
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DNA were added to a 20 µL reaction mixture containing 
1 × PCR buffer (20 mM Tris–HCl pH 8.4, 50 mM KCl, 
1.5 mM of MgCl2), 0.125 mM of dNTPs, 0.25 mM of each 
primer and 1 U Taq DNA polymerase (Qiagen, Hilden, 
Germany). The PCR was run on a PTC-200 Thermal 
cycler (MJ Research, Waltham, USA). Thermal conditions 
after initial denaturation (94 °C, 5 min) were 35 cycles of 
94 °C for 45 s, 65 °C for 1 min, and 72 °C for 1 min. PCR 
reactions were completed with a final extension step of 
72  °C for 5  min. PCR products were visualized through 
electrophoresis on a 1.2 % agarose gel stained with SYBR 
green I in 1x Tris-electrophoresis buffer (90  mM Tris–
acetate, pH 8.0, 90 mM boric acid, 2.5 mM EDTA).
Subsequently, PCR products were purified (Exo-SAP-
IT, USB, Affymetrix, USA) and directly used as templates 
for DNA sequencing using the BigDye terminator v. 1.1 
cycle sequencing kit (Applied Biosystems, Foster City, 
USA) on an ABI 3130XL DNA sequencer. G6PD poly-
morphisms were identified by assembling the sequences 
with the reference sequence of G6PD (NG_009015.2) 
gene using the Codoncode Aligner 4.0 software (http://
www.codoncode.com) and visually reconfirmed from 
their electropherograms.
Statistical analysis
Data were analysed by using GraphPad Prism v. 5.0 for 
windows (GraphPad software, San Diego, CA). The effect 
of G6PD genotypes was determined on initial parasitae-
mia and haemoglobin values using a multivariate regres-
sion model. The children were classified in groups of 
normal, intermediate (female heterozygous) and deficient 
(hemizygous males and homozygous females) individu-
als. To evaluate the effect of G6PD genotypes on haemo-
globin concentrations, the model included adjustment 
for age, gender, centre, weight, temperature and parasi-
taemia. To investigate the G6PD effect on parasitaemia, 
parasite densities were log-transformed and the model 
included adjustment for age, gender, centre, weight, hae-
moglobin levels and temperature. For the construction 
of the multivariate regression model, a subjective model-
building approach that excludes possible confound-
ers such as gender, age and origin of study participants 
was applied. Kruskal–Wallis of One-way ANOVA with 
Dunn’s Multiple Comparison and Mann–Whitney tests 
were used to determine the differences among categories. 
The level of significance was set to a P value of 0.05.
Results
Patients
According to the SMAC definition of severe malaria 
which perfectly reflects the policies of most African 
hospitals [21, 22], the frequency of severe malaria syn-
dromes at presentation were substantially different across 
the three study sites (Table  1). The majority of children 
fulfilled one or more criteria of the WHO definition 
of severe malaria [23, 24], which include severe anae-
mia (haematocrit of  <15  % or Hb  <5  g/dL with a para-
sitaemia of >10,000/μL), hyperlactataemia (≥5 mmol/L), 
hyperparasitaemia (>250,000 parasites/μL), hypoglycae-
mia (whole blood or plasma glucose ≤2.2 mmol/L), and 
haemoglobinuria (urine that is dark red or black, with a 
dipstick that is positive for Hb/myoglobin). A description 
of children screened, recruited and genotyped for their 
G6PD status is shown in Fig.  1. From the 287 malaria 
children enrolled, the G6PD genotypes were available 
for only 278 children. One hundred and forty-six chil-
dren (53 %) were males. The median age was 2 (IQR: 1–4) 
years ranging from 6  months to 10  years with a mean 
haemoglobin value of 8.5 (± 2.4) g/dL.
Prevalence of G6PD genotypes and associations 
with baseline variables
Overall, 202 (73 %) children were classified as G6PD nor-
mal [type B; 114 (78 %) males, 88 (67 %) females], while 
40 (14  %) were female heterozygous (type A+) and 36 
(13  %) were G6PD deficient [type  A−; 32 (22  %) males 
hemizygous and 4 (3 %) female homozygous]. In Table 2, 
the genotype frequencies of G6PD for males and females 
Table 1 Distribution of severe malaria syndromes by study centre
Children can appear in more than one category
a Missing data for some syndromes
All (%) Lambaréné, Gabon (%) Kumasi, Ghana (%) Kisumu, Kenya (%)
Severe malaria syndromes at admissiona
 Respiratory distress 10/278 (4) 1/108 (1) 9/87 (10) 0/83 (0)
 Prostration 55/278 (20) 4/108 (4) 43/87 (49) 8/83 (10)
 Cerebral malaria 13/278 (5) 0/108 (0) 12/87 (14) 1/83 (1)
 General seizure 20/278 (7) 4/108 (4) 13/87 (15) 3/83 (4)
 Severe anaemia 26/278 (9) 5/108 (5) 20/87 (23) 1/83 (1)
 Jaundice 21/278 (8) 0/108 (0) 16/87 (18) 5/83 (6)
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by study site are shown. Between the study centres, there 
was a significant difference (p < 0.0001) in the prevalence 
of A− G6PD deficiency among males. Among females, 
the frequency of A− G6PD deficiency was lower com-
pared to males. The prevalence was 4  % in Lambaréné 
(Gabon), 5  % in Kumasi (Ghana) and 0  % in Kisumu 
(Kenya).
To investigate the association of G6PD genotypes with 
baseline variables, the children were grouped based 
on gender and G6PD genotype. Baseline demographic 
and clinical data are given in Table  3. Using a multi-
variate regression analysis adjusted for age, gender, cen-
tre, weight, temperature and parasitaemia, there was 
a significant association of the G6PD genotypes with 
the adjusted mean baseline of haemoglobin concentra-
tions (p  <  0.0001). Furthermore, a comparison between 
children G6PD normal and heterozygous (p  <  0.0001), 
and between individuals G6PD normal and G6PD defi-
cient (p  =  0.009) showed a significant difference in 
adjusted mean baseline haemoglobin. The G6PD mutant 
Fig. 1 Patient population profile
Table 2 Frequency of G6PD genotypes in malaria children from the three study centres
Data are shown as N (%). G6PD genotype: male normal = A+ or B; male hemizygous = A−; female normal = BB or BA+ or A+A+; female heterozygous = BA− or 
A+A−; female homozygous = A−A−
Country Centre Male, N B A+ A− Female, N BB BA+ A+A+ BA− A+A− A−A−
Gabon Lambaréné 52 28 (54) 9 (17) 15 (29) 56 20 (35) 14 (25) 2 (4) 1 (2) 17 (30) 2 (4)
Ghana Kumasi 46 25 (54) 8 (18) 13 (28) 41 10 (24) 11 (27) 2 (5) 1 (2) 15 (37) 2 (5)
Kenya Kisumu 48 31 (65) 13 (27) 4 (8) 35 22 (63) 7 (20) 0 (0) 0 (0) 6 (17) 0 (0)
Total 146 84 (58) 30 (20) 32 (22) 132 52 (39) 32 (24) 4 (3) 2 (2) 38 (29) 4 (3)
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genotypes were associated with a 2.7  g/dL and 1  g/dL 
decrease in haemoglobin levels in heterozygous and defi-
cient children, respectively. The multivariate regression 
analysis adjusted for age, gender, centre, weight, haemo-
globin levels and temperature did not result in any asso-
ciation (p  =  0.29) of the G6PD genotypes on adjusted 
mean baseline parasite densities. In addition, there was 
no difference in adjusted log mean parasite densities 
between G6PD normal and heterozygous individuals 
(p = 0.18), and between G6PD normal and deficient chil-
dren (p = 0.07).
Severe malarial anaemia and cerebral malaria
Following the WHO guidelines [23] which defines severe 
malarial anaemia (SMA) as Hb <5 g/dL, 26 children (9 %) 
were affected by SMA in this study. The mean haemo-
globin concentrations was 4  g/dL (range 1.9–4.9  g/dL). 
There was no difference (p =  0.66) of the haemoglobin 
levels between SMA children with different G6PD geno-
types. However, SMA occurred more frequently among 
G6PD normal 15/26 (58  %) compared to G6PD het-
erozygous 8/26 (31  %) and G6PD deficient 3/26 (12  %) 
children.
Only 13 patients (5  %) had cerebral malaria. Nine of 
them were G6PD normal and four were female G6PD 
heterozygous.
Discussion
Glucose-6-phosphate dehydrogenase deficiency has 
raised in frequencies in malaria-endemic settings as a 
consequence of the evolutionary pressure exerted by 
malaria on the human genome [16]. A plethora of pre-
vious studies have indicated and suggested a correlation 
between malaria endemicity and the occurrence of G6PD 
deficiency (reviewed in [25]).
The main objective of this study was to assess the dis-
tribution of G6PD genotypes among African children 
from three geographically countries presenting with 
severe malaria and participating in the SMAC clinical 
trial on different artesunate treatment regimens. While 
meanwhile many G6PD variants have been described [8, 
11], the main focus was on the most relevant three vari-
ants (376A (G6PD type B, no deficiency), 376G (moder-
ate G6PD deficiency type A+) and 202A severe G6PD 
deficiency type A−) in Africa [26].
The prevalence of severe G6PD deficiency as deter-
mined genetically was higher compared to previous 
findings from Gabon with 17  % in the present study 
versus 14  % reported earlier among males and 7 vs 2  % 
among females [27]. In Ghana 28  % were observed in 
this study, compared to 9  % among males and 5 vs 3  % 
among females indicated previously [28]. However, in 
Kenya the prevalence of severe G6PD deficiency among 
Table 3 Baseline demographic and clinical data following G6PD genotypes
Values are mean (SD) [range] unless otherwise indicated. G6PD genotype: male normal = A or B; male hemizygous = A−; female normal = B/B or B/A or A/A; female 
homozygous = A−/A−; female heterozygous = B/A− or A/A−
NA not applicable; SD standard deviation
Characteristic Male normal 
(n = 114)
Male hemizygous 
(n = 32)
Female normal 
(n = 88)
Female heterozy-
gous (n = 40)
Female homozy-
gous (n = 4)
All children 
(n = 278)
Age, years [range] 3.3 (2.8) [0–10] 2.6 (2.2) [0–8] 2.2 (1.9) [0–8] 2.3 (2.6) [0–10] 2.5 (3) [0–6] 2.7 (2.5) [0–10]
0–3, n (%) 65 (57) 23 (72) 69 (78) 30 (75) 2 (50) 189 (68)
4–7, n (%) 39 (34) 8 (25) 18 (21) 7 (18) 2 (50) 74 (27)
≥8, n (%) 10 (9) 1 (3) 1 (1) 3 (7) 0 (0) 15 (5)
Weight, kg 15.6 (5.2) 12.6 (4.7) 13.2 (4) 13.2 (5.9) 16.3 (2.7) 14.1 (5)
Parasitemia per μL, geo-
metric mean [range]
150,464 [6240–
1,270,080]
95,369 [8153–
709,400]
138,296 [5377–
1,677,780]
105,520 [6380–
745,100]
172,340 [32,176–
397,440]
132,349 [5377–
1,677,780]
Temperature, °C 37.9 (1.1) 38.4 (1) 38.2 (1.1) 38 (1.2) 37.7 (1.3) 38.1 (1.1)
Haemoglobin, g/dL 
(years)
8.9 (2.4) 7.8 (2.3) 8.9 (2.3) 7.1 (2.3) 8.2 (1.4) 8.5 (2.4)
0–3 8.2 (2.4) 7.6 (2.1) 8.6 (2.3) 6.7 (2.2) 8.1 (2.1) 8.1 (2.4)
4–7 9.9 (2) 8.2 (2.8) 9.7 (1.8) 6.9 (2) 8.3 (1.3) 9.3 (2.2)
≥8 9.8 (1.8) NA NA 10.6 (0.6) NA 10.2 (1.7)
Haematocrit, % 27.4 (7.3) 23.8 (7.1) 27.3 (7) 21.7 (7.6) 25.5 (4) 26.1 (7.5)
Red blood cell count, 
10^12/L
3.8 (1) 3.3 (1.2) 3.6 (1) 3 (1) 3.1 (0.4) 3.6 (1.1)
Platelet count, 10^9/L 151.6 (230.4) 98 (82) 117.3 (118.8) 111 (77.7) 63.3 (30) 127.5 (167.9)
White blood cell count, 
10^9/L
9.4 (4.2) 11.6 (7.9) 9.8 (4.3) 11.6 (4.4) 7.7 (3.4) 10.1 (4.9)
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females was lower compared to previous reports with 
0 vs 5 % and equal among males 8 vs 8 % [29]. Regard-
less of the site, G6PD deficiency was considerably higher 
among males (22 %) compared to females (3 %), with an 
overall prevalence of 13 % across sites. This finding con-
firms that males are affected by this blood disorder rather 
than females and that G6PD deficient females are rather 
uncommon [26].
A significant association of moderately and severely 
deficient G6PD genotypes and haemoglobin levels 
according to the baseline data was observed. In fact, 
compared to children with the normal G6PD genotype 
(haemoglobin median: 9.3  g/dL), G6PD heterozygous 
(haemoglobin median: 6.6 g/dL) and deficient (haemoglo-
bin median: 8.3 g/dL) children had 2.7 and 1 g/dL lower 
haemoglobin concentrations, respectively. The results 
contradict previous findings, which did not observe any 
association between G6PD genotypes and haemoglobin 
levels [30–32]. While in their study, May et al. [32] found 
lower levels of haemoglobin in G6DP deficient individu-
als, the association was not significant. An explanation 
could be the different designs of that and the present 
study. Here, patients with severe malaria were included, 
which implies high parasitaemia and haemoglobin con-
centrations  <5  g/dL, whereas in the above cited study, 
the authors excluded patients with haemoglobin concen-
trations ≤7 g/L [30] and recruited individuals only with 
uncomplicated malaria [31] or who were asymptomati-
cally infected [32].
In the case of SMA, there was no difference of hae-
moglobin levels among children with different G6PD 
genotypes. This may suggest that G6PD deficiency is 
not associated with this complication. However, this is 
in fact surprising especially as a significant difference of 
baseline haemoglobin values between G6PD normal and 
deficient individuals was observed. Moreover, in a large 
case–control study in Kenyan individuals, a significant 
increased risk to severe malarial anaemia associated with 
lower haemoglobin levels in G6PD deficient children 
with severe malaria at the time of hospital admission was 
found [33]. The likely explanation could be due to the 
sample size which was rather small.
Although not significant, parasite densities were lower 
in G6PD deficient children than in G6PD heterozygous, 
compared to G6PD normal individuals. However, this 
trend is in agreement with previous works [34, 35]. Con-
flicting results have been reported regarding parasitae-
mia and the various G6PD genotypes. Other studies have 
indicated a significantly lower parasitaemia associated 
with female G6PD heterozygous individuals, suggesting a 
protective advantage by this genotype [36–39].
In comparison to individuals with uncomplicated 
malaria, this study population was hyperparasitemic 
according to the criteria of severe malaria provided 
by WHO with lower parasitaemia in G6PD deficient 
individuals. However, either in uncomplicated or in 
severe/complicated malaria, G6PD deficiency was 
always associated with lower parasitaemia [30, 33]. 
Although the underlying genetic mechanisms are not 
completely clear, mechanisms suggested are impaired 
growth of P. falciparum parasites in G6PD deficient 
red blood cells [40] and slow rates of parasite replica-
tion [41, 42], more efficient clearance of infected red 
blood cells [43], and lower abundance of P. falciparum 
6-phosphogluconolactonase mRNA in parasites from 
G6PD deficient individuals [44] both uncomplicated 
and severe malaria.
Several limitations apply to this study. Although some 
of the observations are in agreement with previous 
findings, the study group is rather small. The focus was 
only on the G6PD mutations 202G > A and 376A > G, 
although other variants such as A542T, G680T or 
T968C have also been reported to contribute to G6PD 
deficiency, albeit at far lower frequencies. The asso-
ciations observed between G6PD genotypes and the 
baseline clinical parameters at admission could in fact 
also be the result of different circumstances. First, only 
patients with severe malaria were included, which could 
explain the findings, especially as the G6PD deficient 
allele 202A appears to confer protection against cerebral 
malaria and increases the risk of severe malarial anae-
mia [16, 17]. Second, depending on the mechanism of 
protection, G6PD deficiency might be associated with 
delayed presentation to the hospital and be a plausible 
explanation of the differences observed in haemoglo-
bin concentrations at first admission. Third, alpha-tha-
lassaemia, another haemoglobinopathy which has been 
associated with lower haemoglobin levels in alpha-tha-
lassaemic Nigerian children and adults [45] cannot be 
ruled out as a confounding variable as it was not inves-
tigated in this study. The statistical analysis using mul-
tivariable regression model is in part subjective due to 
the adjusted variables added.
Conclusions
G6PD deficiency is more common among children 
from Gabon and Ghana than in Kenya. A significant 
association of the G6PD genotypes studied to lower 
haemoglobin levels was observed, suggesting a pos-
sible contributions of G6PD deficiency to the reduced 
production of erythrocytes in affected individuals. This 
was, however, not related to severe malarial anaemia 
experienced by some children. There was no evidence 
of a significant association between lower parasitaemia 
observed in G6PD deficient individuals compared to 
normal ones.
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